EOS-AX1463 | Reparixin | 266359-83-5 | C14H21NO3S | 283.39 | CC(C)CC1=CC=C(C=C1)C(C)C(=O)NS(=O)(=O)C |
EOS-AX1464 | Reparixin L-lysine salt | 266359-93-7 | C20H35N3O5S | 429.57 | CC(C)CC1=CC=C(C=C1)C(C)C(=O)NS(=O)(=O)C.C(CCN)CC(C(=O)O)N |
EOS-AX1465 | RepSox | 446859-33-2 | C17H13N5 | 287.32 | CC1=CC=CC(=N1)C2=C(C=NN2)C3=NC4=C(C=C3)N=CC=C4 |
EOS-AX1466 | Resminostat hydrochloride | 1187075-34-8 | C16H20ClN3O4S | 385.87 | CN(C)CC1=CC=C(S(=O)(N2C=C(/C=C\C(NO)=O)C=C2)=O)C=C1.Cl |
EOS-AX1467 | Retaspimycin | 857402-23-4 | C31H45N3O8 | 587.7 | CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=C(C(=C2O)C1)NCC=C)O)C)OC)OC(=O)N)C)C)O)OC |
EOS-AX1468 | Retigabine | 150812-12-7 | C16H18FN3O2 | 303.33 | |
EOS-AX1469 | Retigabine dihydrochloride | 150812-13-8 | C16H20Cl2FN3O2 | 376.25 | CCOC(=O)NC1=C(C=C(C=C1)NCC2=CC=C(C=C2)F)N.Cl.Cl |
EOS-AX1470 | Retinyl glucoside | 136778-12-6 | C26H40O6 | 448.59 | CC1(C)CCCC(C)=C1/C=C\C(C)=C\C=C\C(C)=C\CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2 |
EOS-AX1471 | Reversine | 656820-32-5 | C21H27N7O | 393.49 | C1CCC(CC1)NC2=NC(=NC3=C2NC=N3)NC4=CC=C(C=C4)N5CCOCC5 |
EOS-AX1472 | RG2833 | 1215493-56-3 | C20H25N3O2 | 339.43 | CC1=CC=C(C=C1)C(=O)NCCCCCC(=O)NC2=CC=CC=C2N |
EOS-AX1473 | RG7112 | 939981-39-2 | C38H48Cl2N4O4S | 727.78 | CCOC1=C(C=CC(=C1)C(C)(C)C)C2=NC(C(N2C(=O)N3CCN(CC3)CCCS(=O)(=O)C)(C)C4=CC=C(C=C4)Cl)(C)C5=CC=C(C=C5)Cl |
EOS-AX1474 | RG7388 | 1229705-06-9 | C31H29Cl2F2N3O4 | 616.48 | CC(C)(C)CC1C(C(C(N1)C(=O)NC2=C(C=C(C=C2)C(=O)O)OC)C3=C(C(=CC=C3)Cl)F)(C#N)C4=C(C=C(C=C4)Cl)F |
EOS-AX1475 | RI-1 | 415713-60-9 | C14H11Cl3N2O3 | 361.61 | C1COCCN1C2=C(C(=O)N(C2=O)C3=CC(=C(C=C3)Cl)Cl)Cl |
EOS-AX1476 | Rilpivirine | 500287-72-9 | C22H18N6 | 366.42 | CC1=CC(=CC(=C1NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C)C=CC#N |
EOS-AX1477 | Rimonabant hydrochloride | 158681-13-1 | C22H22Cl4N4O | 500.25 | CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl.Cl |
EOS-AX1478 | Riociguat | 625115-55-1 | C20H19FN8O2 | 422.42 | CN(C1=C(N=C(N=C1N)C2=NN(C3=C2C=CC=N3)CC4=CC=CC=C4F)N)C(=O)OC |
EOS-AX1479 | Rivastigmine | 123441-03-2 | C14H22N2O2 | 250.34 | CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C |
EOS-AX1480 | RJR-2403 | 15585-43-0 | C10H14N2 | 162.23 | CNCCC=CC1=CN=CC=C1 |
EOS-AX1481 | RJR-2403 oxalate | 220662-95-3 | C12H16N2O4 | 252.27 | CNCCC=CC1=CN=CC=C1.C(=O)(C(=O)O)O |
EOS-AX1482 | RKI-1447 | 1342278-01-6 | C16H14N4O2S | 326.37 | C1=CC(=CC(=C1)O)CNC(=O)NC2=NC(=CS2)C3=CC=NC=C3 |
EOS-AX1483 | RO-9187 | 876708-03-1 | C9H12N6O5 | 284.23 | C1=CN(C(=O)N=C1N)C2C(C(C(O2)(CO)N=[N+]=[N-])O)O |
EOS-AX1484 | ROCK inhibitor | 867017-68-3 | C18H13ClF2N6O | 402.79 | CC1=CNC2=NC=CC(=C12)OC3=C(C=C(C=C3F)NC4=CC(=NC(=N4)N)Cl)F |
EOS-AX1485 | ROCK inhibitor-1 | 1415565-02-4 | C16H21N7O2 | 343.39 | |
EOS-AX1486 | Rocuronium | 143558-00-3 | C32H53N2O4+ | 529.77 | CC(OC1C([N+]2(CC=C)CCCC2)CC3C1(C)CCC4C3CCC5C4(C)CC(N6CCOCC6)C(O)C5)=O |
EOS-AX1487 | Rotigotine | 99755-59-6 | C19H25NOS | 315.47 | CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O |
EOS-AX1488 | Rotigotine hydrochloride | 125572-93-2 | C19H26ClNOS | 351.93 | CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O.Cl |
EOS-AX1489 | RS 127445 | 199864-87-4 | C17H16FN3 | 281.33 | FC1=CC=C(C2=CC(C(C)C)=NC(N)=N2)C3=CC=CC=C31 |
EOS-AX1490 | RS 504393 | 300816-15-3 | C25H27N3O3 | 417.5 | CC1=CC2=C(NC(OC23CCN(CCC4=C(C)OC(C5=CC=CC=C5)=N4)CC3)=O)C=C1 |
EOS-AX1491 | RU 58841 | 154992-24-2 | C17H18F3N3O3 | 369.35 | CC1(C(=O)N(C(=O)N1CCCCO)C2=CC(=C(C=C2)C#N)C(F)(F)F)C |
EOS-AX1492 | Ruxolitinib phosphate | 1092939-17-7 | C17H21N6O4P | 404.36 | [HH].C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OOP(=O)=O |
EOS-AX1493 | Ruxolitinib sulfate | 1092939-16-6 | C17H20N6O4S | 404.44 | N#CCC(N1C=C(C2=C3C=CNC3=NC=N2)C=N1)C4CCCC4.OS(=O)(O)=O |
EOS-AX1494 | S0859 | 1019331-10-2 | C29H24ClN3O3S | 530.04 | CC1=CC=C(CN(C(C2=CC=CC=C2Cl)=O)CC3=CC=C(C4=CC=CC=C4S(=O)(NC#N)=O)C=C3)C=C1 |
EOS-AX1495 | Safinamide | 133865-89-1 | C17H19FN2O2 | 302.34 | CC(C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)F |
EOS-AX1496 | Salinomycin | 53003-10-4 | C42H70O11 | 751 | CCC(C1CCC(C(O1)C(C)C(C(C)C(=O)C(CC)C2C(CC(C3(O2)C=CC(C4(O3)CCC(O4)(C)C5CCC(C(O5)C)(CC)O)O)C)C)O)C)C(=O)O |
EOS-AX1497 | Salinomycin sodium salt | 55721-31-8 | C42H70NaO11+ | 773.99 | CCC(C1CCC(C(O1)C(C)C(C(C)C(=O)C(CC)C2C(CC(C3(O2)C=CC(C4(O3)CCC(O4)(C)C5CCC(C(O5)C)(CC)O)O)C)C)O)C)C(=O)O.[Na] |
EOS-AX1498 | Salirasib | 162520-00-5 | C22H30O2S | 358.54 | CC(=CCCC(=CCCC(=CCSC1=CC=CC=C1C(=O)O)C)C)C |
EOS-AX1499 | Salmefamol | 18910-65-1 | C19H25NO4 | 331.41 | CC(NCC(O)C1=CC(CO)=C(O)C=C1)CC2=CC=C(OC)C=C2 |
EOS-AX1500 | Salmeterol xinafoate | 94749-08-3 | C36H45NO7 | 603.75 | C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O.C1=CC=C2C(=C1)C=CC(=C2O)C(=O)O |
EOS-AX1501 | Saquinavir | 127779-20-8 | C38H50N6O5 | 670.84 | CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O |
EOS-AX1502 | Saquinavir mesylate | 149845-06-7 | C39H54N6O8S | 766.95 | CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O.CS(=O)(=O)O |
EOS-AX1503 | SB 239063 | 193551-21-2 | C20H21FN4O2 | 368.4 | COC1=NC=CC(C2=C(C3=CC=C(F)C=C3)N=CN2C4CCC(O)CC4)=N1 |
EOS-AX1504 | SB 271046 hydrochloride | 209481-24-3 | C20H23Cl2N3O3S2 | 488.45 | CC1=C(SC2=C1C=C(C=C2)Cl)S(=O)(=O)NC3=CC(=C(C=C3)OC)N4CCNCC4.Cl |
EOS-AX1505 | SB1317 | 937270-47-8 | C23H24N4O | 372.46 | CN(C/C=C/CCOC1=CC=CC2=C1)CC3=CC(NC4=NC=CC2=N4)=CC=C3 |
EOS-AX1506 | SB-222200 | 174635-69-9 | C26H24N2O | 380.48 | CCC(C1=CC=CC=C1)NC(=O)C2=C(C(=NC3=CC=CC=C32)C4=CC=CC=C4)C |
EOS-AX1507 | SB-269970 | 201038-74-6 | C18H28N2O3S | 352.49 | CC1CCN(CCC2CCCN2S(=O)(C3=CC=CC(O)=C3)=O)CC1 |
EOS-AX1508 | SB-277011 | 215803-78-4 | C28H30N4O | 438.56 | N#CC1=CC2=C(C=C1)CN(CC2)CCC3CCC(NC(C4=CC=NC5=CC=CC=C45)=O)CC3 |
EOS-AX1509 | SB-408124 Hydrochloride | 1431697-90-3 | C19H19ClF2N4O | 392.83 | CC1=CC(/N=C(O)/NC2=CC=C(N(C)C)C=C2)=C3C=C(F)C=C(F)C3=N1.Cl |
EOS-AX1510 | SB-505124 hydrochloride | 356559-13-2 | C20H22ClN3O2 | 371.86 | CC1=CC=CC(=N1)C2=C(N=C(N2)C(C)(C)C)C3=CC4=C(C=C3)OCO4.Cl |
EOS-AX1511 | SB-674042 | 483313-22-0 | C24H21FN4O2S | 448.51 | CC1=NC(=C(S1)C2=CC=CC=C2F)C(=O)N3CCCC3CC4=NN=C(O4)C5=CC=CC=C5 |
EOS-AX1512 | SCD inhibitor | 1032229-33-6 | C20H22ClN3O3 | 387.87 | |
EOS-AX1513 | SCH 527123 | 473727-83-2 | C21H23N3O5 | 397.42 | CCC(C1=CC=C(O1)C)NC2=C(C(=O)C2=O)NC3=CC=CC(=C3O)C(=O)N(C)C |
EOS-AX1514 | SCH 563705 | 473728-58-4 | C23H27N3O5 | 425.48 | CCC(C1=CC(=CO1)C(C)C)NC2=C(C(=O)C2=O)NC3=CC=CC(=C3O)C(=O)N(C)C |
EOS-AX1515 | SCH-1473759 | 1094069-99-4 | C20H26N8OS | 426.54 | CCN(CC1=NSC(=C1)NC2=NC(=CN3C2=NC=C3C4=CNN=C4)C)C(C)(C)CO |
EOS-AX1516 | SCH772984 | 942183-80-4 | C33H33N9O2 | 587.67 | C1CN(CC1C(=O)NC2=CC3=C(C=C2)NN=C3C4=CC=NC=C4)CC(=O)N5CCN(CC5)C6=CC=C(C=C6)C7=NC=CC=N7 |
EOS-AX1517 | SCH900776 S-isomer | 891494-64-7 | C15H18BrN7 | 376.25 | NC1=C(Br)C([C@@H]2CNCCC2)=NC3=C(C4=CN(C)N=C4)C=NN13 |
EOS-AX1518 | SD-06 | 271576-80-8 | C20H20ClN5O2 | 397.86 | ClC(C=C1)=CC=C1C2=NNC(C3CCN(C(CO)=O)CC3)=C2C4=NC=NC=C4 |
EOS-AX1519 | SD-208 | 627536-09-8 | C17H10ClFN6 | 352.75 | C1=CC(=C(C=C1Cl)C2=NC3=NC=CN=C3C(=N2)NC4=CC=NC=C4)F |
EOS-AX1520 | SDZ 220-581 | 174575-17-8 | C16H17ClNO5P | 369.74 | O=P(O)(O)CC1=CC(C2=CC=CC=C2Cl)=CC(CC(N)C(O)=O)=C1 |
EOS-AX1521 | SDZ 220-581 Ammonium salt | 179411-94-0 | C16H20ClN2O5P | 386.77 | ClC1=CC=CC=C1C2=CC(C[C@@](N)([H])C(O)=O)=CC(CP(O)(O)=O)=C2.N |
EOS-AX1522 | SEA0400 | 223104-29-8 | C21H19F2NO3 | 371.38 | CCOC1=CC(=C(C=C1)OC2=CC=C(C=C2)OCC3=C(C=CC(=C3)F)F)N |
EOS-AX1523 | Secalciferol | 55721-11-4 | C27H44O3 | 416.64 | CC(CCC(C(C)(C)O)O)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C |
EOS-AX1524 | Senicapoc | 289656-45-7 | C20H15F2NO | 323.35 | C1=CC=C(C=C1)C(C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)C(=O)N |
EOS-AX1525 | Seocalcitol | 134404-52-7 | C30H46O3 | 454.7 | CCC(CC)(C=CC=CC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C)O |
EOS-AX1526 | Setiptiline | 57262-94-9 | C19H19N | 261.36 | [H]C1([H])C(C2=C([H])C([H])=C([H])C([H])=C2C([H])([H])C3=C([H])C([H])=C([H])C([H])=C43)=C4C([H])([H])N(C([H])([H])[H])C1([H])[H] |
EOS-AX1527 | Setiptiline maleate | 85650-57-3 | C23H23NO4 | 377.43 | O=C(/C([H])=C([H])\C(O[H])=O)O[H].[H]C1([H])C(C2=C([H])C([H])=C([H])C([H])=C2C([H])([H])C3=C([H])C([H])=C([H])C([H])=C43)=C4C([H])([H])N(C([H])([H])[H])C1([H])[H] |
EOS-AX1528 | Sildenafil | 139755-83-2 | C22H30N6O4S | 474.58 | CCCC1=NN(C2=C1NC(=NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C |
EOS-AX1529 | Silvestrol | 697235-38-4 | C34H38O13 | 654.66 | COC1C(OC(CO1)C(CO)O)OC2=CC(=C3C(=C2)OC4(C3(C(C(C4C5=CC=CC=C5)C(=O)OC)O)O)C6=CC=C(C=C6)OC)OC |
EOS-AX1530 | Silvestrol aglycone | 960365-65-5 | C27H26O8 | 478.49 | |
EOS-AX1531 | Simeprevir | 923604-59-5 | C38H47N5O7S2 | 749.96 | COC1=CC=C(C(O[C@H]2CC(C(N(C)CCCC/C=C\[C@H]3C[C@@]3(C(NS(=O)(C4CC4)=O)=O)NC5=O)=O)[C@H]5C2)=CC(C6=NC(C(C)C)=CS6)=N7)C7=C1C |
EOS-AX1532 | SRT2104 (GSK2245840) | 1093403-33-8 | C26H24N6O2S2 | 516.64 | CC1=C(SC(=N1)C2=CN=CC=C2)C(=O)NC3=CC=CC=C3C4=CN5C(=CSC5=N4)CN6CCOCC6 |
EOS-AX1533 | sitaxsentan | 184036-34-8 | C18H15ClN2O6S2 | 454.9 | CC1=CC2=C(OCO2)C=C1CC(C3=C(S(=O)(NC4=C(Cl)C(C)=NO4)=O)C=CS3)=O |
EOS-AX1534 | SJB2-043 | 63388-44-3 | C17H9NO3 | 275.26 | C1=CC=C(C=C1)C2=NC3=C(O2)C(=O)C4=CC=CC=C4C3=O |
EOS-AX1535 | Skepinone-L | 1221485-83-1 | C24H21F2NO4 | 425.42 | C1CC2=C(C=CC(=C2)NC3=C(C=C(C=C3)F)F)C(=O)C4=C1C=CC(=C4)OCC(CO)O |
EOS-AX1536 | SLx-2119 | 911417-87-3 | C26H24N6O2 | 452.51 | O=C(C([H])([H])OC1=C([H])C([H])=C([H])C(C2=NC3=C([H])C([H])=C([H])C([H])=C3C(N([H])C(C([H])=C4[H])=C([H])C5=C4N([H])N=C5[H])=N2)=C1[H])N([H])C(C([H])([H])[H])([H])C([H])([H])[H] |
EOS-AX1537 | SMIP004 | 143360-00-3 | C13H19NO | 205.3 | CCCCC1=CC(=C(C=C1)NC(=O)C)C |
EOS-AX1538 | SMND-309 | 1065559-56-9 | C18H14O8 | 358.3 | C1=CC(=C(C=C1C=C(C2=C(C=CC(=C2O)O)C=CC(=O)O)C(=O)O)O)O |
EOS-AX1539 | Sobetirome | 211110-63-3 | C20H24O4 | 328.4 | CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)C(C)C)C)OCC(=O)O |
EOS-AX1540 | sodium 4-pentynoate | 101917-30-0 | C5H5NaO2 | 120.08 | C#CCCC(=O)[O-].[Na+] |
EOS-AX1541 | Sodium Channel inhibitor 1 | 1198117-23-5 | C24H19F4N3O3 | 473.42 | C1=CC=NC(=C1)CCN2C(C3=C(C2=O)C=CC=C3F)C(=O)NCC4=CC=C(C=C4)OC(F)(F)F |
EOS-AX1542 | Sodium formononetin-3'-sulfonate | 949021-68-5 | C16H13NaO7S | 372.33 | COC1=C(C=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)O)S(=O)(=O)O.[Na] |
EOS-AX1543 | Solasodine | 126-17-0 | C27H43NO2 | 413.64 | [H]C(C1([H])C(C(C([H])([H])C([H])([H])C2([H])O[H])(C([H])([H])[H])C(C2([H])[H])=C([H])C1([H])[H])([H])C([H])([H])C3([H])[H])(C4([H])[H])C3(C([H])([H])[H])C(C5([H])C([H])([H])[H])([H])C4([H])OC65N([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])C6([H])[H] |
EOS-AX1544 | SPK-601 | 1096687-52-3 | C11H15KOS2 | 266.47 | S=C(S[K])O[C@H]1C[C@]2([H])C3([H])[C@](CCC3)([H])[C@@]1([H])C2 |
EOS-AX1545 | SQ109 | 502487-67-4 | C22H38N2 | 330.55 | CC(=CCCC(=CCNCCNC1C2CC3CC(C2)CC1C3)C)C |
EOS-AX1546 | SR1078 | 1246525-60-9 | C17H10F9NO2 | 431.25 | C1=CC(=CC=C1C(=O)NC2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O)C(F)(F)F |
EOS-AX1547 | SR3335 | 293753-05-6 | C13H9F6NO3S2 | 405.34 | C1=CSC(=C1)S(=O)(=O)NC2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O |
EOS-AX1548 | DL-α-Hydroxyglutaric acid disodium salt | 40951-21-1 | C5H6Na2O5 | 192.08 | OC(C([O-])=O)CCC([O-])=O.[Na+].[Na+] |
EOS-AX1549 | SRT3109 | 1204707-71-0 | C18H23F2N5O4S2 | 475.53 | CC(NC1=CC(NS(=O)(N2CCC2)=O)=NC(SCC3=C(F)C(F)=CC=C3)=N1)C(O)CO |
EOS-AX1550 | SRT3190 | 1204707-73-2 | C18H23F2N5O4S2 | 475.54 | CC(C(CO)O)NC1=CC(=NC(=N1)SCC2=C(C(=CC=C2)F)F)NS(=O)(=O)N3CCC3 |
EOS-AX1551 | ST 2825 | 894787-30-5 | C27H28Cl2N4O5S | 591.51 | C1CC2(CC3N(C2=O)C(CCS3)C(=O)N)N(C1)C(=O)CC4=CC=C(C=C4)NC(=O)COC5=C(C=C(C=C5)Cl)Cl |
EOS-AX1552 | ST-836 | 1148156-63-1 | C23H34N4OS | 414.61 | CCCN(CCN1CCN(CC1)C2=CC=CC=C2OC)C3CCC4=C(C3)SC=N4 |
EOS-AX1553 | ST-836 hydrochloride | 1415564-68-9 | C23H35ClN4OS | 451.07 | CCCN(CCN1CCN(CC1)C2=CC=CC=C2OC)C3CCC4=C(C3)SC=N4.Cl |
EOS-AX1554 | SU 5402 | 215543-92-3 | C17H16N2O3 | 296.33 | CC1=CNC(=C1CCC(=O)O)C=C2C3=CC=CC=C3NC2=O |
EOS-AX1555 | SU14813 | 627908-92-3 | C23H27FN4O4 | 442.48 | CC1=C(/C=C2C3=C(NC/2=O)C=CC(F)=C3)NC(C)=C1C(NCC(O)CN4CCOCC4)=O |
EOS-AX1556 | SU14813 double bond Z | 452105-23-6 | C23H27FN4O4 | 442.48 | CC1=C(NC(=C1C(=O)NCC(CN2CCOCC2)O)C)C=C3C4=C(C=CC(=C4)F)NC3=O |
EOS-AX1557 | SU14813 maleate | 849643-15-8 | C27H31FN4O8 | 558.56 | CC1=C(NC(=C1C(=O)NCC(CN2CCOCC2)O)C)C=C3C4=C(C=CC(=C4)F)NC3=O.C(=CC(=O)O)C(=O)O |
EOS-AX1558 | SU5416 | 204005-46-9 | C15H14N2O | 238.28 | CC1=CC(=C(N1)C=C2C3=CC=CC=C3NC2=O)C |
EOS-AX1559 | Tacalcitol | 57333-96-7 | C27H44O3 | 416.65 | CC(C)C(CCC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C)O |
EOS-AX1560 | Tacalcitol monohydrate | 93129-94-3 | C27H46O4 | 434.65 | CC(C)C(CCC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C)O.O |
EOS-AX1561 | TAK-242 | 243984-11-4 | C15H17ClFNO4S | 361.82 | CCOC(=O)C1=CCCCC1S(=O)(=O)NC2=C(C=C(C=C2)F)Cl |
EOS-AX1562 | TAK-242 S enantiomer | 243984-10-3 | C15H17ClFNO4S | 361.82 | CCOC(=O)C1=CCCCC1S(=O)(=O)NC2=C(C=C(C=C2)F)Cl |
EOS-AX1563 | TAK-700 salt | 426219-53-6 | C28H28N4O7 | 532.54 | CNC(C1=CC2=C(C=C(C3(O)CCN4C3=CN=C4)C=C2)C=C1)=O.O=C(C(O)C(O)C(O)=O)NC5=CC=CC=C5 |
EOS-AX1564 | Talarozole | 201410-53-9 | C21H23N5S | 377.51 | CCC(CC)C(C1=CC=C(C=C1)NC2=NC3=CC=CC=C3S2)N4C=NC=N4 |
EOS-AX1565 | Talnetant | 174636-32-9 | C25H22N2O2 | 382.45 | CCC(C1=CC=CC=C1)NC(=O)C2=C(C(=NC3=CC=CC=C32)C4=CC=CC=C4)O |
EOS-AX1566 | Talnetant hydrochloride | 204519-66-4 | C25H23ClN2O2 | 418.92 | CCC(C1=CC=CC=C1)NC(=O)C2=C(C(=NC3=CC=CC=C32)C4=CC=CC=C4)O.Cl |
EOS-AX1567 | Tamibarotene | 94497-51-5 | C22H25NO3 | 351.44 | CC1(CCC(C2=C1C=CC(=C2)NC(=O)C3=CC=C(C=C3)C(=O)O)(C)C)C |
EOS-AX1568 | Tanaproget | 304853-42-7 | C16H15N3OS | 297.37 | CC1(C2=C(C=CC(=C2)C3=CC=C(N3C)C#N)NC(=S)O1)C |
EOS-AX1569 | Taranabant | 701977-09-5 | C27H25ClF3N3O2 | 515.97 | CC(C(CC1=CC=C(C=C1)Cl)C2=CC=CC(=C2)C#N)NC(=O)C(C)(C)OC3=NC=C(C=C3)C(F)(F)F |
EOS-AX1570 | Tariquidar methanesulfonate, hydrate | 625375-83-9 | C40H52N4O15S2 | 892.99 | COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC.CS(=O)(=O)O.CS(=O)(=O)O.O.O.O |
EOS-AX1571 | Tasquinimod | 254964-60-8 | C20H17F3N2O4 | 406.36 | CN1C2=C(C(=CC=C2)OC)C(=C(C1=O)C(=O)N(C)C3=CC=C(C=C3)C(F)(F)F)O |
EOS-AX1572 | TBB | 17374-26-4 | C6HBr4N3 | 434.71 | C1(=C(C2=NNN=C2C(=C1Br)Br)Br)Br |
EOS-AX1573 | TC-DAPK 6 | 315694-89-4 | C17H12N2O2 | 276.29 | C1=CC=C(C=C1)C=CC2=NC(=CC3=CN=CC=C3)C(=O)O2 |
EOS-AX1574 | Tedizolid | 856866-72-3 | C17H15FN6O3 | 370.34 | CN1N=C(N=N1)C2=NC=C(C=C2)C3=C(C=C(C=C3)N4CC(OC4=O)CO)F |
EOS-AX1575 | Tegobuvir | 1000787-75-6 | C25H14F7N5 | 517.4 | C1=CC=C(C(=C1)C2=NC3=CN(C=CC3=N2)CC4=NN=C(C=C4)C5=C(C=C(C=C5)C(F)(F)F)C(F)(F)F)F |
EOS-AX1576 | Teneligliptin hydrobromide | 906093-29-6 | C44H65Br5N12O2S2 | 1257.72 | CC1=NN(C(=C1)N2CCN(CC2)C3CC(NC3)C(=O)N4CCSC4)C5=CC=CC=C5.CC1=NN(C(=C1)N2CCN(CC2)C3CC(NC3)C(=O)N4CCSC4)C5=CC=CC=C5.Br.Br.Br.Br.Br |
EOS-AX1577 | Testosterone | 58-22-0 | C19H28O2 | 288.42 | |
EOS-AX1578 | Tezampanel | 154652-83-2 | C13H21N5O2 | 279.34 | C1CC2CNC(CC2CC1CCC3=NNN=N3)C(=O)O |
EOS-AX1579 | TG 100572 | 867334-05-2 | C26H26ClN5O2 | 475.97 | CC1=C2C(=CC(=C1)C3=C(C=CC(=C3)O)Cl)N=NC(=N2)NC4=CC=C(C=C4)OCCN5CCCC5 |
EOS-AX1580 | TG 100572 Hydrochloride | 867331-64-4 | C26H27Cl2N5O2 | 512.43 | CC1=C2C(=CC(=C1)C3=C(C=CC(=C3)O)Cl)N=NC(=N2)NC4=CC=C(C=C4)OCCN5CCCC5.Cl |
EOS-AX1581 | TG 100801 | 867331-82-6 | C33H30ClN5O3 | 580.08 | CC1=C2C(=CC(=C1)C3=C(C=CC(=C3)OC(=O)C4=CC=CC=C4)Cl)N=NC(=N2)NC5=CC=C(C=C5)OCCN6CCCC6 |
EOS-AX1582 | TG 100801 Hydrochloride | 1018069-81-2 | C33H31Cl2N5O3 | 616.54 | CC1=C2C(N=NC(NC3=CC=C(OCCN4CCCC4)C=C3)=N2)=CC(C5=C(Cl)C=CC(OC(C6=CC=CC=C6)=O)=C5)=C1.Cl |
EOS-AX1583 | TH-302 | 918633-87-1 | C9H16Br2N5O4P | 449.04 | CN1C(=CN=C1[N+](=O)[O-])COP(=O)(NCCBr)NCCBr |
EOS-AX1584 | Tianeptine | 66981-73-5 | C21H25ClN2O4S | 436.96 | CN1C2=CC=CC=C2C(C3=C(S1(=O)=O)C=C(C=C3)Cl)NCCCCCCC(=O)O |
EOS-AX1585 | Tiotropium Bromide | 136310-93-5 | C19H22BrNO4S2 | 472.42 | O=C(C(C1=C([H])C([H])=C([H])S1)(C2=C([H])C([H])=C([H])S2)O[H])O[C@@]3([H])C([H])([H])[C@]4([H])[N+](C([H])([H])[H])(C([H])([H])[H])[C@@](C3([H])[H])([H])[C@@]5([H])O[C@@]45[H].[Br-] |
EOS-AX1586 | Tipiracil hydrochloride | 183204-72-0 | C9H12Cl2N4O2 | 279.12 | C1CC(=N)N(C1)CC2=C(C(=O)NC(=O)N2)Cl.Cl |
EOS-AX1587 | Tipranavir | 174484-41-4 | C31H33F3N2O5S | 602.66 | CCCC1(CC(=C(C(=O)O1)C(CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4 |
EOS-AX1588 | Tirofiban hydrochloride monohydrate | 150915-40-5 | C22H39ClN2O6S | 495.07 | O=C(O)[C@@H](NS(=O)(CCCC)=O)CC1=CC=C(OCCCCC2CCNCC2)C=C1.Cl.O |
EOS-AX1589 | TMC353121 | 857066-90-1 | C32H42N6O3 | 558.71 | CC1=CC(=C(C=C1)CCCO)NCC2=CC3=C(C=C2)N=C(N3CC4=C(C=CC(=N4)C)O)NCCCN5CCOCC5 |
EOS-AX1590 | Toceranib | 356068-94-5 | C22H25FN4O2 | 396.46 | CC1=C(NC(=C1C(=O)NCCN2CCCC2)C)C=C3C4=C(C=CC(=C4)F)NC3=O |
EOS-AX1591 | Toceranib phosphate | 874819-74-6 | C22H28FN4O6P | 494.45 | CC1=C(NC(=C1C(=O)NCCN2CCCC2)C)C=C3C4=C(C=CC(=C4)F)NC3=O.OP(=O)(O)O |
EOS-AX1592 | Toll-like receptor modulator | 926927-42-6 | C15H13F5N2O2 | 348.28 | CCOC(=O)C1=CC2=C(C=C(C=C2)C(C(F)(F)F)(F)F)N=C(C1)N |
EOS-AX1593 | Toltrazuril sulfone | 69004-04-2 | C18H14F3N3O6S | 457.38 | CC1=C(OC2=CC=C(S(=O)(C(F)(F)F)=O)C=C2)C=CC(N3C(NC(N(C)C3=O)=O)=O)=C1 |
EOS-AX1594 | Tonabersat | 175013-84-0 | C20H19ClFNO4 | 391.82 | CC(=O)C1=CC2=C(C=C1)OC(C(C2NC(=O)C3=CC(=C(C=C3)F)Cl)O)(C)C |
EOS-AX1595 | Toremifene | 89778-26-7 | C26H28ClNO | 405.96 | CN(CCOC1=CC=C(/C(C2=CC=CC=C2)=C(C3=CC=CC=C3)\CCCl)C=C1)C |
EOS-AX1596 | Tozadenant | 870070-55-6 | C19H26N4O4S | 406.5 | CC1(CCN(CC1)C(=O)NC2=NC3=C(C=CC(=C3S2)N4CCOCC4)OC)O |
EOS-AX1597 | Trabectedin | 114899-77-3 | C39H43N3O11S | 761.84 | CC1=C(OC)C(O)=C2C3[C@@H]4[C@@H]5C6=C(C7=C(OCO7)C(C)=C6OC(C)=O)[C@@H](COC(C8(C9=CC(OC)=C(O)C=C9CCN8)CS5)=O)N4C(O)C(CC2=C1)N3C |
EOS-AX1598 | Trametinib DMSO solvate | 1187431-43-1 | C28H29FIN5O5S | 693.53 | CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC(=CC=C4)NC(=O)C)C5CC5.CS(=O)C |
EOS-AX1599 | Trelagliptin | 865759-25-7 | C18H20FN5O2 | 357.38 | CN1C(=O)C=C(N(C1=O)CC2=C(C=CC(=C2)F)C#N)N3CCCC(C3)N |
EOS-AX1600 | Trelagliptin succinate | 1029877-94-8 | C22H26FN5O6 | 475.47 | CN1C(=O)C=C(N(C1=O)CC2=C(C=CC(=C2)F)C#N)N3CCCC(C3)N.C(CC(=O)O)C(=O)O |
EOS-AX1601 | Trenbolone | 10161-33-8 | C18H22O2 | 270.37 | |
EOS-AX1602 | Triptolide | 38748-32-2 | C20H24O6 | 360.41 | CC(C)C12C(O1)C3C4(O3)C5(CCC6=C(C5CC7C4(C2O)O7)COC6=O)C |
EOS-AX1603 | Triptonide | 38647-11-9 | C20H22O6 | 358.39 | CC([C@]12[C@](O2)([H])[C@@](O3)([H])[C@@]43[C@]5(CCC6=C([C@]5([H])C[C@@](O7)([H])[C@@]47C1=O)COC6=O)C)C |
EOS-AX1604 | Troglitazone | 97322-87-7 | C24H27NO5S | 441.54 | CC1=C(C(=C2CCC(OC2=C1C)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C)O |
EOS-AX1605 | TTP 22 | 329907-28-0 | C16H14N2O2S2 | 330.42 | CC1=CC=C(C=C1)C2=CSC3=C2C(=NC=N3)SCCC(=O)O |
EOS-AX1606 | TUG-770 | 1402601-82-4 | C19H14FNO2 | 307.32 | C1=CC=C(C(=C1)CC#N)C#CC2=CC(=C(C=C2)CCC(=O)O)F |
EOS-AX1607 | Tulathromycin A | 217500-96-4 | C41H79N3O12 | 806.08 | CCCNCC1(O)C(C)OC(OC2C(C)C(OC3C(O)C(N(C)C)CC(C)O3)C(C)(O)CC(C)CNC(C)C(O)C(C)(O)C(CC)OC(C2C)=O)CC1(OC)C |
EOS-AX1608 | Tyrosine kinase inhibitor | 1021950-26-4 | C31H31FN6O5 | 586.61 | O=C(NC1=CC=C(OC2=C3C=C(C(NCCN4CCOCC4)=O)NC3=NC=C2)C=C1)C5(C(NC6=CC=C(F)C=C6)=O)CC5 |
EOS-AX1609 | UK-5099 | 56396-35-1 | C18H12N2O2 | 288.3 | C1=CC=C(C=C1)N2C=C(C3=CC=CC=C32)C=C(C#N)C(=O)O |
EOS-AX1610 | Umeclidinium bromide | 869113-09-7 | C29H34BrNO2 | 508.49 | C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5.[Br-] |
EOS-AX1611 | UNC1215 | 1415800-43-9 | C32H43N5O2 | 529.72 | C1CCN(C1)C2CCN(CC2)C(=O)C3=CC(=C(C=C3)C(=O)N4CCC(CC4)N5CCCC5)NC6=CC=CC=C6 |
EOS-AX1612 | VAL-083 | 23261-20-3 | C6H10O4 | 146.14 | C1C(O1)C(C(C2CO2)O)O |
EOS-AX1613 | Valaciclovir | 124832-26-4 | C13H20N6O4 | 324.34 | CC(C(N)C(OCCOCN1C=NC2=C1NC(N)=NC2=O)=O)C |
EOS-AX1614 | Valganciclovir | 88110-89-8 | C11H15N5O5 | 297.27 | CC(OCC(OCN1C=NC2=C1NC(N)=NC2=O)CO)=O |
EOS-AX1615 | Valspodar | 121584-18-7 | C63H111N11O12 | 1214.62 | CC=CCC(C)C(=O)C1C(=O)NC(C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C)C(C)C |
EOS-AX1616 | Vandetanib hydrochloride | 524722-52-9 | C22H25BrClFN4O2 | 511.81 | CN1CCC(COC2=C(OC)C=C(C(NC3=C(F)C=C(Br)C=C3)=NC=N4)C4=C2)CC1.Cl |
EOS-AX1617 | Vandetanib trifluoroacetate | 338992-53-3 | C24H25BrF4N4O4 | 589.38 | CN1CCC(COC2=C(OC)C=C(C(NC3=C(F)C=C(Br)C=C3)=NC=N4)C4=C2)CC1.FC(F)(F)C(O)=O |
EOS-AX1618 | Vaniprevir | 923590-37-8 | C38H55N5O9S | 757.94 | CCC1CC1(NC(C2CC3CN2C(C(C(C)(C)C)NC(OCC(C)(C)CCCCC4=C5CN(C(O3)=O)CC5=CC=C4)=O)=O)=O)C(NS(=O)(C6CC6)=O)=O |
EOS-AX1619 | VCH-916 | 1200133-34-1 | C26H36KNO4S | 497.73 | CC1CCC(C(N(C2=C(C([O-])=O)SC(C3=CCCCC3)=C2)C4CCC(OC)CC4)=O)CC1.[K+] |
EOS-AX1620 | Vc-MMAD | 1401963-17-4 | C70H104N12O14S | 1369.71 | CC[C@]([C@@](N(C([C@](/N=C(O)/[C@](N(C(OCC1=CC=C(NC([C@](/N=C(O)/[C@](/N=C(O)/CCCCCN2C(C=CC2=O)=O)([H])C(C)C)([H])CCCNC(O)=N)=O)C=C1)=O)C)([H])C(C)C)([H])C(C)C)=O)C)([H])[C@@](OC)([H])CC(N3CCC[C@@]3([H])[C@@](OC)([H])[C@@](/C(O)=N/[C@@](C4=NC=CS4)([H])CC5 |
EOS-AX1621 | VcMMAE | 646502-53-6 | C68H105N11O15 | 1316.63 | CCC(C(N(C(C(NC(C(N(C(OCC1=CC=C(NC(C(NC(C(NC(CCCCCN2C(C=CC2=O)=O)=O)C(C)C)=O)CCCNC(N)=O)=O)C=C1)=O)C)C(C)C)=O)C(C)C)=O)C)C(OC)CC(N3CCCC3C(OC)C(C(NC(C(O)C4=CC=CC=C4)C)=O)C)=O)C |
EOS-AX1622 | VD2-D3 | 1217448-46-8 | C28H41D3O | 399.67 | CC(C)C(C)C=CC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C |
EOS-AX1623 | Verlukast | 120443-16-5 | C26H27ClN2O3S2 | 515.09 | CN(C(CCSC(SCCC(O)=O)C1=CC=CC(/C=C/C2=NC3=C(C=C2)C=CC(Cl)=C3)=C1)=O)C |
EOS-AX1624 | Vernakalant | 794466-70-9 | C20H31NO4 | 349.46 | COC1=C(OC)C=C(CCOC2CCCCC2N3CCC(O)C3)C=C1 |
EOS-AX1625 | Vernakalant Hydrochloride | 748810-28-8 | C20H32ClNO4 | 385.93 | COC1=C(C=C(C=C1)CCOC2CCCCC2N3CCC(C3)O)OC.Cl |
EOS-AX1626 | Vicriviroc maleate | 599179-03-0 | C32H42F3N5O6 | 649.7 | CC1CN(C2(C)CCN(C(C3=C(C)N=CN=C3C)=O)CC2)CCN1C(C4=CC=C(C(F)(F)F)C=C4)COC.O=C(O)/C=C/C(O)=O |
EOS-AX1627 | Vigabatrin | 68506-86-5 | C6H11NO2 | 129.16 | C=C[C@](N)([H])CCC(O)=O |
EOS-AX1628 | Vilazodone | 163521-12-8 | C26H27N5O2 | 441.52 | C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N |
EOS-AX1629 | Vilazodone Hydrochloride | 163521-08-2 | C26H28ClN5O2 | 477.99 | C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N.Cl |
EOS-AX1630 | Vinblastine sulfate | 143-67-9 | C46H60N4O13S | 909.05 | CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O |
EOS-AX1631 | Vinorelbine ditartrate | 125317-39-7 | C53H66N4O20 | 1079.11 | CCC1=CC2CC(C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC.C(C(C(=O)O)O)(C(=O)O)O.C(C(C(=O)O)O)(C(=O)O)O |
EOS-AX1632 | Vitamin D4 | 511-28-4 | C28H46O | 398.66 | CC(C)C(C)CCC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C |
EOS-AX1633 | VO-Ohpic trihydrate | 476310-60-8 | C12H15N2O11V+ | 414.2 | |
EOS-AX1634 | Voreloxin | 175414-77-4 | C18H19N5O4S | 401.44 | CNC1CN(CC1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(=O)O |
EOS-AX1635 | Voreloxin Hydrochloride | 175519-16-1 | C18H20ClN5O4S | 437.9 | CNC1CN(CC1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(=O)O.Cl |
EOS-AX1636 | Vortioxetine | 508233-74-7 | C18H22N2S | 298.45 | CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C |
EOS-AX1637 | VS-5584 (SB2343) | 1246560-33-7 | C17H22N8O | 354.41 | CC1=NC2=C(N=C(N=C2N1C(C)C)N3CCOCC3)C4=CN=C(N=C4)N |
EOS-AX1638 | VTP-27999 | 942142-51-0 | C26H41ClN4O5 | 525.08 | CNC(CNC(N1CCCC(C(OCCNC(OC)=O)C2=CC(Cl)=CC=C2)C1)=O)CC3CCCOC3 |
EOS-AX1639 | VTP-27999 2,2,2-trifluoroacetate | 1013937-63-7 | C28H42ClF3N4O7 | 639.1 | CNC(CC1CCCOC1)CNC(=O)N2CCCC(C2)C(C3=CC(=CC=C3)Cl)OCCNC(=O)OC.C(=O)(C(F)(F)F)O |
EOS-AX1640 | VTP-27999 Hydrochloride | 1264191-73-2 | C26H42Cl2N4O5 | 561.54 | CNC(CC1CCCOC1)CNC(=O)N2CCCC(C2)C(C3=CC(=CC=C3)Cl)OCCNC(=O)OC.Cl |
EOS-AX1641 | VX-11e | 896720-20-0 | C24H20Cl2FN5O2 | 500.35 | CC1=CN=C(N=C1C2=CNC(=C2)C(=O)NC(CO)C3=CC(=CC=C3)Cl)NC4=C(C=C(C=C4)F)Cl |
EOS-AX1642 | WAY 316606 | 915759-45-4 | C18H19F3N2O4S2 | 448.48 | C1CNCCC1NS(=O)(=O)C2=C(C=CC(=C2)S(=O)(=O)C3=CC=CC=C3)C(F)(F)F |
EOS-AX1643 | WAY-100635 | 162760-96-5 | C25H34N4O2 | 422.56 | COC1=CC=CC=C1N2CCN(CC2)CCN(C3=CC=CC=N3)C(=O)C4CCCCC4 |
EOS-AX1644 | WAY-100635 maleate salt | 634908-75-1 | C29H38N4O6 | 538.64 | COC1=CC=CC=C1N2CCN(CC2)CCN(C3=CC=CC=N3)C(=O)C4CCCCC4.C(=CC(=O)O)C(=O)O |
EOS-AX1645 | WEHI-539 | 1431866-33-9 | C31H29N5O3S2 | 583.72 | C1CC2=C(C=C(C=C2)C3=NC(=C(S3)CCCOC4=CC=C(C=C4)CN)C(=O)O)C(=NNC5=NC6=CC=CC=C6S5)C1 |
EOS-AX1646 | WHI-P97 | 211555-05-4 | C16H13Br2N3O3 | 455.11 | COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C(=C3)Br)O)Br)OC |
EOS-AX1647 | XL019 | 945755-56-6 | C25H28N6O2 | 444.53 | C1CC(NC1)C(=O)NC2=CC=C(C=C2)C3=NC(=NC=C3)NC4=CC=C(C=C4)N5CCOCC5 |
EOS-AX1648 | XL-147 | 934526-89-3 | C25H25ClN6O4S | 541.02 | |
EOS-AX1649 | XL228 | 898280-07-4 | C22H31N9O | 437.54 | CC(C)C1=NOC(=C1)CNC2=NC(=CC(=N2)NC3=NNC(=C3)C4CC4)N5CCN(CC5)C |
EOS-AX1650 | XL388 | 1251156-08-7 | C23H22FN3O4S | 455.5 | CC1=C(C=CC(=C1F)S(=O)(=O)C)C(=O)N2CCOC3=C(C2)C=C(C=C3)C4=CN=C(C=C4)N |
EOS-AX1651 | XL765 | 1123889-87-1 | C31H29N5O6S | 599.67 | CC1=C(C=C(C=C1)C(=O)NC2=CC=C(C=C2)S(=O)(=O)NC3=NC4=CC=CC=C4N=C3NC5=CC(=CC(=C5)OC)OC)OC |
EOS-AX1652 | XMD17-109 | 1435488-37-1 | C36H46N8O3 | 638.8 | CN1CCN(C2CCN(C(C3=CC(OCC)=C(NC4=NC=C5C(N(C6CCCC6)C(C=CC=C7)=C7C(N5C)=O)=N4)C=C3)=O)CC2)CC1 |
EOS-AX1653 | XMD8-92 | 1234480-50-2 | C26H30N6O3 | 474.57 | CCOC1=C(C=CC(=C1)N2CCC(CC2)O)NC3=NC=C4C(=N3)N(C5=CC=CC=C5C(=O)N4C)C |
EOS-AX1654 | X-NeuNAc | 160369-85-7 | C19H21BrClN2NaO9 | 559.72 | CC(=O)NC1C(CC(OC1C(C(CO)O)O)(C(=O)[O-])OC2=CNC3=C2C(=C(C=C3)Br)Cl)O.[Na+] |
EOS-AX1655 | Y-33075 | 199433-58-4 | C16H16N4O | 280.32 | CC(N)C1=CC=C(C(NC2=C3C=CNC3=NC=C2)=O)C=C1 |
EOS-AX1656 | YK-4-279 | 1037184-44-3 | C17H13Cl2NO4 | 366.2 | COC1=CC=C(C=C1)C(=O)CC2(C3=C(C=CC(=C3NC2=O)Cl)Cl)O |
EOS-AX1657 | YM-155 hydrochloride | 355406-09-6 | C20H19ClN4O3 | 398.84 | CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Cl-] |
EOS-AX1658 | YS-49 | 132836-42-1 | C20H20BrNO2 | 386.28 | OC1=C(O)C=C2C(CC3=CC=CC4=CC=CC=C43)NCCC2=C1.Br |
EOS-AX1659 | Zaltidine | 85604-00-8 | C8H10N6S | 222.27 | CC1=NC=C(N1)C2=CSC(=N2)N=C(N)N |
EOS-AX1660 | Zardaverine | 101975-10-4 | C12H10F2N2O3 | 268.22 | COC1=C(OC(F)F)C=CC(C2=NNC(C=C2)=O)=C1 |
EOS-AX1661 | Zaurategrast | 455264-31-0 | C26H25BrN4O3 | 521.42 | C1CCC2(CC1)C(=C(C2=O)Br)NC(CC3=CC=C(C=C3)NC4=NC=CC5=C4C=NC=C5)C(=O)O |
EOS-AX1662 | Ziprasidone | 146939-27-7 | C21H21ClN4OS | 412.94 | C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54 |
EOS-AX1663 | Ziprasidone hydrochloride monohydrate | 138982-67-9 | C21H24Cl2N4O2S | 467.41 | C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl |
EOS-AX1664 | ZM323881 | 193001-14-8 | C22H18FN3O2 | 375.4 | CC1=CC(=C(C=C1O)NC2=NC=NC3=C2C=CC(=C3)OCC4=CC=CC=C4)F |
EOS-AX1665 | Zolpidem | 82626-48-0 | C19H21N3O | 307.39 | |
EOS-AX1666 | Zosuquidar | 167354-41-8 | C32H31F2N3O2 | 527.6 | FC1([C@@](C2=C([H])C([H])=C([H])C([H])=C23)([H])[C@]1([H])C4=C([H])C([H])=C([H])C([H])=C4C3([H])N5C([H])([H])C([H])([H])N(C([H])([H])[C@@](C([H])([H])OC6=C([H])C([H])=C([H])C7=C6C([H])=C([H])C([H])=N7)([H])O[H])C([H])([H])C5([H])[H])F |
EOS-AX1667 | Batimastat sodium salt | 130464-84-5 | C23H30N3NaO4S2 | 499.62 | CNC([C@@H](NC([C@@H]([C@H](CSC1=CC=CS1)C(NO[Na])=O)CC(C)C)=O)CC2=CC=CC=C2)=O |
EOS-AX1668 | Veliparib dihydrochloride | 912445-05-7 | C13H18Cl2N4O | 317.21 | CC1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N.Cl.Cl |
EOS-AX1669 | Pemetrexed disodium | 150399-23-8 | C20H19N5Na2O6 | 471.37 | |
EOS-AX1670 | Necrostatin 2 racemate | 852391-15-2 | C13H12ClN3O2 | 277.71 | ClC1=CC=CC2=C1NC=C2CC3NC(N(C)C3=O)=O |
EOS-AX1671 | Necrostatin 2 S enantiomer | 852391-20-9 | C13H12ClN3O2 | 277.71 | ClC1=CC=CC2=C1NC=C2C[C@H]3C(N(C)C(N3)=O)=O |
EOS-AX1672 | AZD1208 | 1204144-28-4 | C21H21N3O2S | 379.48 | C1CC(CN(C1)C2=C(C=CC=C2C=C3C(=O)NC(=O)S3)C4=CC=CC=C4)N |
EOS-AX1673 | A-769662 | 844499-71-4 | C20H12N2O3S | 360.39 | C1=CC=C(C(=C1)C2=CC=C(C=C2)C3=CSC4=C3C(=C(C(=O)N4)C#N)O)O |
EOS-AX1674 | AN-2728 | 906673-24-3 | C14H10BNO3 | 251.05 | |
EOS-AX1675 | BI 2536 | 755038-02-9 | C28H39N7O3 | 521.67 | CCC1C(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C(C=C4)C(=O)NC5CCN(CC5)C)OC)C |
EOS-AX1676 | Doxorubicin | 23214-92-8 | C27H29NO11 | 543.52 | CC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)CO)O)N)O |
EOS-AX1677 | Lapatinib Ditosylate | 388082-78-8 | C29H26ClFN4O4S 2C7H8O3S | 925.46 | CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl |
EOS-AX1678 | PF-03716556 | 928774-43-0 | C22H26N4O3 | 394.48 | CC1=C2C(CCOC2=CC=C1)NC3=CC(=CN4C3=NC(=C4)C)C(=O)N(C)CCO |
EOS-AX1679 | Vatalanib | 212141-54-3 | C20H15ClN4 | 346.81 | C1=CC=C2C(=C1)C(=NN=C2NC3=CC=C(C=C3)Cl)CC4=CC=NC=C4 |
EOS-AX1680 | CHR 2797 | 238750-77-1 | C21H30N2O6 | 406.5 | |
EOS-AX1681 | IU1 | 314245-33-5 | C18H21FN2O | 300.37 | CC1=CC(=C(N1C2=CC=C(C=C2)F)C)C(=O)CN3CCCC3 |
EOS-AX1682 | LDN 57444 | 668467-91-2 | C17H11Cl3N2O3 | 397.64 | CC(=O)ON=C1C2=C(C=CC(=C2)Cl)N(C1=O)CC3=C(C=CC(=C3)Cl)Cl |
EOS-AX1683 | NSC 632839 hydrochloride | 157654-67-6 | C21H21NO.HCl | 339.86 | CC1=CC=C(C=C1)C=C2CNCC(=CC3=CC=C(C=C3)C)C2=O.Cl |
EOS-AX1684 | RO4929097 | 847925-91-1 | C22H20F5N3O3 | 469.4 | CC(C)(C(=O)NCC(C(F)(F)F)(F)F)C(=O)NC1C2=CC=CC=C2C3=CC=CC=C3NC1=O |
EOS-AX1685 | MK-0752 | 471905-41-6 | C21H21ClF2O4S | 442.9 | C1CC(CCC1CCC(=O)O)(C2=C(C=CC(=C2)F)F)S(=O)(=O)C3=CC=C(C=C3)Cl |
EOS-AX1686 | MLN9708 | 1201902-80-8 | C20H23BCl2N2O9 | 517.1 | B1(OC(=O)CC(O1)(CC(=O)O)C(=O)O)C(CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl |
EOS-AX1687 | MLN2238 | 1072833-77-2 | C14H19BCl2N2O4 | 361 | B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O |
EOS-AX1688 | CEP-18770 | 847499-27-8 | C21H28BN3O5 | 413.3 | B(C(CC(C)C)NC(=O)C(C(C)O)NC(=O)C1=CC=CC(=N1)C2=CC=CC=C2)(O)O |
EOS-AX1689 | Salinosporamide A (NPI-0052, Marizomib) | 437742-34-2 | C15H20ClNO4 | 313.78 | CC12C(C(=O)NC1(C(=O)O2)C(C3CCCC=C3)O)CCCl |
EOS-AX1690 | ONX-0914 (PR-957) | 960374-59-8 | C31H40N4O7 | 580.67 | CC(C(=O)NC(CC1=CC=C(C=C1)OC)C(=O)NC(CC2=CC=CC=C2)C(=O)C3(CO3)C)NC(=O)CN4CCOCC4 |
EOS-AX1691 | Gabexate mesylate | 56974-61-9 | C16H23N3O4.CH4O3S | 417.48 | CCOC(=O)C1=CC=C(C=C1)OC(=O)CCCCCN=C(N)N.CS(=O)(=O)O |
EOS-AX1692 | Aspirin (Acetylsalicylic acid) | 50-78-2 | C9H8O4 | 180.16 | CC(=O)OC1=CC=CC=C1C(=O)O |
EOS-AX1693 | Artemether (SM-224) | 71963-77-4 | C16H26O5 | 298.4 | [H][C@]12[C@@]3([C@@]4([H])CC[C@@]2([H])C)[C@@](O[C@H](OC)[C@@]4(C)[H])([H])O[C@@](OO3)(C)CC1 |
EOS-AX1694 | Disulfiram | 97-77-8 | C10H20N2S4 | 296.54 | CCN(CC)C(=S)SSC(=S)N(CC)CC |
EOS-AX1695 | Apoptosis Activator 2 | 79183-19-0 | C15H9Cl2NO2 | 306.1 | C1=CC=C2C(=C1)C(=O)C(=O)N2CC3=CC(=C(C=C3)Cl)Cl |
EOS-AX1696 | YO-01027 (Dibenzazepine, DBZ) | 209984-56-5 | C26H23F2N3O3 | 463.48 | CC(C(=O)NC1C2=CC=CC=C2C3=CC=CC=C3N(C1=O)C)NC(=O)CC4=CC(=CC(=C4)F)F |
EOS-AX1697 | LY-411575 | 209984-57-6 | C26H23F2N3O4 | 479.48 | CC(C(=O)NC1C2=CC=CC=C2C3=CC=CC=C3N(C1=O)C)NC(=O)C(C4=CC(=CC(=C4)F)F)O |
EOS-AX1698 | LY2811376 | 1194044-20-6 | C15H14F2N4S | 320.4 | CC1(CCSC(=N1)N)C2=C(C=C(C(=C2)C3=CN=CN=C3)F)F |
EOS-AX1699 | LY-900009 | 209984-68-9 | C23H27N3O4 | 409.48 | CN1C([C@@H](NC([C@H](C)NC([C@@H](O)C(C)C)=O)=O)C2=C(C=CC=C2)C3=C1C=CC=C3)=O |
EOS-AX1700 | BMS-708163 (Avagacestat) | 1146699-66-2 | C20H17ClF4N4O4S | 520.88 | C1=CC(=CC=C1S(=O)(=O)N(CC2=C(C=C(C=C2)C3=NOC=N3)F)C(CCC(F)(F)F)C(=O)N)Cl |
EOS-AX1701 | LY3039478 | 1421438-81-4 | C22H23F3N4O4 | 464.44 | CC(C(=O)NC1C2=CC=CC=C2C3=C(N=CC=C3)N(C1=O)CCO)NC(=O)CCC(F)(F)F |
EOS-AX1702 | Danoprevir (RG7227) | 850876-88-9 | C35H46FN5O9S | 731.83 | FC1=CC=CC2=C1CN(C2)C(O[C@@H]3C[C@](C(N[C@@]4(C(NS(=O)(C5CC5)=O)=O)[C@@](/C=C\CCCCC[C@@H]6N([H])C(OC(C)(C)C)=O)([H])C4)=O)([H])N(C6=O)C3)=O |
EOS-AX1703 | BMS-790052 | 1214735-16-6 | C40H50N8O6 | 738.9 | |
EOS-AX1704 | BMS-790052 2HCl | 1009119-65-6 | C40H52Cl2N8O6 | 811.8 | |
EOS-AX1705 | Boceprevir (SCH-503034) | 394730-60-0 | C27H45N5O5 | 519.7 | |
EOS-AX1706 | Telaprevir (VX-950) | 402957-28-2 | C36H53N7O6 | 679.9 | CCCC(C(=O)C(=O)NC1CC1)NC(=O)C2C3CCCC3CN2C(=O)C(C(C)(C)C)NC(=O)C(C4CCCCC4)NC(=O)C5=NC=CN=C5 |
EOS-AX1707 | VX-222 (VCH-222, Lomibuvir) | 1026785-59-0 | C25H35NO4S | 445.6 | CC1CCC(CC1)C(=O)N(C2CCC(CC2)O)C3=C(SC(=C3)C#CC(C)(C)C)C(=O)O |
EOS-AX1708 | Glimepiride | 93479-97-1 | C24H34N4O5S | 490.62 | CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C |
EOS-AX1709 | Linagliptin (BI-1356) | 668270-12-0 | C25H28N8O2 | 472.5 | CC#CCN1C2=C(N=C1N3CCCC(C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C |
EOS-AX1710 | Saxagliptin (BMS-477118) | 361442-04-8 | C18H25N3O2 | 315.4 | |
EOS-AX1711 | Sitagliptin phosphate monohydrate | 654671-77-9 | C16H15F6N5O.H3PO4.H2O | 523.3 | [HH].C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)CC(CC3=CC(=C(C=C3F)F)F)N.O.OOP(=O)=O |
EOS-AX1712 | Vildagliptin (LAF-237) | 274901-16-5 | C17H25N3O2 | 303.4 | C1CC(N(C1)C(=O)CNC23CC4CC(C2)CC(C4)(C3)O)C#N |
EOS-AX1713 | Alogliptin (SYR-322) | 850649-61-5 | C18H21N5O2 | 339.39 | CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N |
EOS-AX1714 | Atazanavir sulfate (BMS-232632-05) | 229975-97-7 | C38H52N6O7.H2SO4 | 802.9 | CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC.OS(=O)(=O)O |
EOS-AX1715 | Deuterated Atazanivir-D3-1 | 1092540-56-1 | C38H37D15N6O7 | 719.95 | O=C(OC([2H])([2H])[2H])N[C@@H](C(C)(C)C)C(NN(C[C@H](O)[C@@H](NC([C@@H](NC(OC([2H])([2H])[2H])=O)C(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])=O)CC1=CC=CC=C1)CC2=CC=C(C3=NC=CC=C3)C=C2)=O |
EOS-AX1716 | Deuterated Atazanivir-D3-2 | 1092540-51-6 | C38H43D9N6O7 | 713.91 | O=C(OC)N[C@@H](C(C)(C)C)C(NN(C[C@H](O)[C@@H](NC([C@@H](NC(OC)=O)C(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])=O)CC1=CC=CC=C1)CC2=CC=C(C3=NC=CC=C3)C=C2)=O |
EOS-AX1717 | Deuterated Atazanivir-D3-3 | 1092540-52-7 | C38H34D18N6O7 | 722.97 | O=C(OC)N[C@@H](C(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])C(NN(CC1=CC=C(C2=NC=CC=C2)C=C1)C[C@H](O)[C@H](CC3=CC=CC=C3)NC([C@H](C(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])NC(OC)=O)=O)=O |
EOS-AX1718 | Marimastat | 154039-60-8 | C15H29N3O5 | 331.41 | CC(C)CC(C(C(=O)NO)O)C(=O)NC(C(=O)NC)C(C)(C)C |
EOS-AX1719 | GM 6001 | 142880-36-2 | C20H28N4O4 | 388.46 | CC(C)CC(CC(=O)NO)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC |
EOS-AX1720 | NSC 405020 | 7497-07-6 | C12H15Cl2NO | 260.16 | CCCC(C)NC(=O)C1=CC(=C(C=C1)Cl)Cl |
EOS-AX1721 | Doxycycline hyclate | 24390-14-5 | C22H24N2O8.HC | 480.9 | O=C(C1=C(O)[C@]2(O)[C@]([C@@H](O)[C@@]3([H])C(C2=O)=C(O)C4=C(O)C=CC=C4[C@@H]3C)([H])[C@H](N(C)C)C1=O)N.Cl |
EOS-AX1722 | 17-AAG (KOS953) | 75747-14-7 | C31H43N3O8 | 585.7 | CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)C)OC)OC(=O)N)C)C)O)OC |
EOS-AX1723 | AT13387 | 912999-49-6 | C24H31N3O3 | 409.5 | CC(C)C1=C(C=C(C(=C1)C(=O)N2CC3=C(C2)C=C(C=C3)CN4CCN(CC4)C)O)O |
EOS-AX1724 | AUY922 (NVP-AUY922) | 747412-49-3 | C26H31N3O5 | 465.5 | CCNC(=O)C1=C(C(=C2C=C(C(=CC2=O)O)C(C)C)ON1)C3=CC=C(C=C3)CN4CCOCC4 |
EOS-AX1725 | BIIB021 | 848695-25-0 | C14H15ClN6O | 318.8 | CC1=CN=C(C(=C1OC)C)CN2C=NC3=C2N=C(N=C3Cl)N |
EOS-AX1726 | Geldanamycin | 30562-34-6 | C29H40N2O9 | 560.6 | CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)OC)C)OC)OC(=O)N)C)C)O)OC |
EOS-AX1727 | IPI-504 (Retaspimycin hydrochloride) | 857402-63-2 | C31H46ClN3O8 | 624.2 | CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=C(C(=C2O)C1)NCC=C)O)C)OC)OC(=O)N)C)C)O)OC.Cl |
EOS-AX1728 | KW-2478 | 819812-04-9 | C30H42N2O9 | 574.66 | CCC1=C(C=C(C(=C1CC(=O)N(CCOC)CCOC)C(=O)C2=CC(=C(C=C2)OCCN3CCOCC3)OC)O)O |
EOS-AX1729 | MPC-3100 | 958025-66-6 | C22H25BrN6O4S | 549.4 | CC(C(=O)N1CCC(CC1)CCN2C3=C(C(=NC=N3)N)N=C2SC4=C(C=C5C(=C4)OCO5)Br)O |
EOS-AX1730 | NVP-BEP800 | 847559-80-2 | C21H23Cl2N5O2S | 480.4 | CCNC(=O)C1=CC2=C(N=C(N=C2S1)N)C3=CC(=C(C=C3Cl)Cl)OCCN4CCCC4 |
EOS-AX1731 | PF-04929113 (SNX-5422) | 908115-27-5 | C25H30F3N5O4 | 521.5 | CC1(CC2=C(C(=O)C1)C(=NN2C3=CC(=C(C=C3)C(=O)N)NC4CCC(CC4)OC(=O)CN)C(F)(F)F)C |
EOS-AX1732 | Radicicol | 12772-57-5 | C18H17ClO6 | 364.78 | CC1CC2C(O2)C=CC=CC(=O)CC3=C(C(=CC(=C3Cl)O)O)C(=O)O1 |
EOS-AX1733 | SNX-2112 | 908112-43-6 | C23H27F3N4O3 | 464.48 | CC1(CC2=C(C(=O)C1)C(=NN2C3=CC(=C(C=C3)C(=O)N)NC4CCC(CC4)O)C(F)(F)F)C |
EOS-AX1734 | BMS-707035 | 729607-74-3 | C17H19FN4O5S | 410.4 | CN1C(=O)C(=C(N=C1N2CCCCS2(=O)=O)C(=O)NCC3=CC=C(C=C3)F)O |
EOS-AX1735 | Elvitegravir (GS-9137) | 697761-98-1 | C23H23ClFNO5 | 447.9 | CC(C)C(CO)N1C=C(C(=O)C2=CC(=C(C=C21)OC)CC3=C(C(=CC=C3)Cl)F)C(=O)O |
EOS-AX1736 | Fluorouracil (Adrucil) | 51-21-8 | C4H3FN2O2 | 130.1 | C1=C(C(=O)NC(=O)N1)F |
EOS-AX1737 | MK-2048 | 869901-69-9 | C21H21ClFN5O4 | 461.9 | CCN1CC(N2C3=C(C(=C2C1=O)O)C(=O)N(N=C3C(=O)NC)CC4=CC(=C(C=C4)F)Cl)C |
EOS-AX1738 | Raltegravir (MK-0518) | 518048-05-0 | C20H21FN6O5 | 444.4 | CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F |
EOS-AX1739 | S/GSK1349572 | 1051375-16-6 | C20H19F2N3O5 | 419.4 | CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O |
EOS-AX1740 | BIBR 953 (Dabigatran, Pradaxa) | 211914-51-1 | C25H25N7O3 | 471.5 | CN1C2=C(C=C(C=C2)C(=O)N(CCC(=O)O)C3=CC=CC=N3)N=C1CNC4=CC=C(C=C4)C(=N)N |
EOS-AX1741 | Captopril | 62571-86-2 | C9H15NO3S | 217.3 | CC(CS)C(=O)N1CCCC1C(=O)[O-] |
EOS-AX1742 | Fosinopril sodium | 88889-14-9 | C30H45NO7P.Na | 585.64 | CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2CC(CC2C(=O)[O-])C3CCCCC3.[Na+] |
EOS-AX1743 | Moxonidine | 75438-57-2 | C9H12ClN5O | 241.68 | CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC |
EOS-AX1744 | Olmesartan (RNH6270, CS-088) | 144689-24-7 | C24H26N6O3 | 446.5 | |
EOS-AX1745 | Olmesartan medoxomil | 144689-63-4 | C29H30N6O6 | 558.6 | CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O |
EOS-AX1746 | Rocilinostat (ACY-1215) | 1316214-52-4 | C24H27N5O3 | 433.5 | C1=CC=C(C=C1)N(C2=CC=CC=C2)C3=NC=C(C=N3)C(=O)NCCCCCCC(=O)NO |
EOS-AX1747 | Vorinostat (SAHA, MK0683) | 149647-78-9 | C14H20N2O3 | 264.3 | C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO |
EOS-AX1748 | Mocetinostat (MGCD0103, MG0103) | 726169-73-9 | C23H20N6O | 396.44 | C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC3=NC=CC(=N3)C4=CN=CC=C4 |
EOS-AX1749 | JNJ-26481585 | 875320-29-9 | C21H26N6O2 | 394.48 | CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO |
EOS-AX1750 | PCI-34051 | 950762-95-5 | C17H16N2O3 | 296.32 | COC1=CC=C(C=C1)CN2C=CC3=C2C=C(C=C3)C(=O)NO |
EOS-AX1751 | CUDC-101 | 1012054-59-9 | C24H26N4O4 | 434.49 | COC1=C(C=C2C(=C1)N=CN=C2NC3=CC=CC(=C3)C#C)OCCCCCCC(=O)NO |
EOS-AX1752 | ITF2357 (Givinostat) | 732302-99-7 | C24H27N3O4.HCl.H2O | 475.97 | CCN(CC)CC1=CC2=C(C=C(COC(NC3=CC=C(C(NO)=O)C=C3)=O)C=C2)C=C1.O.Cl |
EOS-AX1753 | MC1568 | 852475-26-4 | C17H15FN2O3 | 314.31 | CN1C=C(C=C1C=CC(=O)NO)C=CC(=O)C2=CC(=CC=C2)F |
EOS-AX1754 | Pracinostat (SB939) | 929016-96-6 | C20H30N4O2 | 358.48 | CCCCC1=NC2=C(N1CCN(CC)CC)C=CC(=C2)C=CC(=O)NO |
EOS-AX1755 | Belinostat (PXD101) | 414864-00-9 | C15H14N2O4S | 318.35 | C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO |
EOS-AX1756 | CUDC-907 | 1339928-25-4 | C23H24N8O4S | 508.55 | CN(CC1=CC2=C(S1)C(=NC(=N2)C3=CN=C(C=C3)OC)N4CCOCC4)C5=NC=C(C=N5)C(=O)NO |
EOS-AX1757 | PCI-24781 (CRA-024781) | 783355-60-2 | C21H23N3O5 | 397.42 | CN(C)CC1=C(OC2=CC=CC=C21)C(=O)NCCOC3=CC=C(C=C3)C(=O)NO |
EOS-AX1758 | Valproic acid sodium salt (Sodium valproate) | 1069-66-5 | C8H15NaO2 | 166.19 | CCCC(CCC)C(=O)[O-].[Na+] |
EOS-AX1759 | Droxinostat | 99873-43-5 | C11H14ClNO3 | 243.69 | CC1=C(C=CC(=C1)Cl)OCCCC(=O)NO |
EOS-AX1760 | Tubastatin A | 1252003-15-8 | C20H21N3O2 | 335.4 | CN(C1)CCC2=C1C3=C(N2CC4=CC=C(C(NO)=O)C=C4)C=CC=C3 |
EOS-AX1761 | CI994 (Tacedinaline) | 112522-64-2 | C15H15N3O2 | 269.3 | CC(=O)NC1=CC=C(C=C1)C(=O)NC2=CC=CC=C2N |
EOS-AX1762 | LAQ824 (NVP-LAQ824,Dacinostat) | 404951-53-7 | C22H25N3O3 | 379.46 | C1=CC=C2C(=C1)C(=CN2)CCN(CCO)CC3=CC=C(C=C3)C=CC(=O)NO |
EOS-AX1763 | AR-42 (OSU-HDAC42) | 935881-37-1 | C18H20N2O3 | 312.36 | CC(C)C(C1=CC=CC=C1)C(=O)NC2=CC=C(C=C2)C(=O)NO |
EOS-AX1764 | M344 | 251456-60-7 | C16H25N3O3 | 307.39 | CN(C)C1=CC=C(C=C1)C(=O)NCCCCCCC(=O)NO |
EOS-AX1765 | Scriptaid | 287383-59-9 | C18H18N2O4 | 326.35 | C1=CC2=C3C(=C1)C(=O)N(C(=O)C3=CC=C2)CCCCCC(=O)NO |
EOS-AX1766 | Sodium Phenylbutyrate | 1716-12-7 | C10H11O2.Na | 186.18 | C1=CC=C(C=C1)CCCC(=O)[O-].[Na+] |
EOS-AX1767 | Resminostat (RAS2410) | 864814-88-0 | C16H19N3O4S | 349.4 | CN(C)CC1=CC=C(C=C1)S(=O)(=O)N2C=CC(=C2)C=CC(=O)NO |
EOS-AX1768 | MLN8237 (Alisertib) | 1028486-01-2 | C27H20ClFN4O4 | 518.92 | COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC |
EOS-AX1769 | VX-680 (MK-0457,Tozasertib) | 639089-54-6 | C23H28N8OS | 464.59 | CC1=CC(=NN1)NC2=NC(=NC(=C2)N3CCN(CC3)C)SC4=CC=C(C=C4)NC(=O)C5CC5 |
EOS-AX1770 | Barasertib (AZD1152-HQPA) | 722544-51-6 | C26H30FN7O3 | 507.56 | CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCO |
EOS-AX1771 | ZM 447439 | 331771-20-1 | C29H31N5O4 | 513.59 | COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=C(C=C3)NC(=O)C4=CC=CC=C4)OCCCN5CCOCC5 |
EOS-AX1772 | MLN8054 | 869363-13-3 | C25H15ClF2N4O2 | 476.86 | C1C2=CN=C(N=C2C3=C(C=C(C=C3)Cl)C(=N1)C4=C(C=CC=C4F)F)NC5=CC=C(C=C5)C(=O)O |
EOS-AX1773 | JNJ-7706621 | 443797-96-4 | C15H12F2N6O3S | 394.36 | C1=CC(=C(C(=C1)F)C(=O)N2C(=NC(=N2)NC3=CC=C(C=C3)S(=O)(=O)N)N)F |
EOS-AX1774 | Danusertib (PHA-739358) | 827318-97-8 | C26H30N6O3 | 474.55 | CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=NNC4=C3CN(C4)C(=O)C(C5=CC=CC=C5)OC |
EOS-AX1775 | AT9283 | 896466-04-9 | C19H23N7O2 | 381.43 | C1CC1NC(=O)NC2=CNNC2=C3N=C4C=CC(=CC4=N3)CN5CCOCC5 |
EOS-AX1776 | Hesperadin | 422513-13-1 | C29H32N4O3S | 516.65 | CCS(=O)(=O)NC1=CC2=C(C=C1)NC(=O)C2=C(C3=CC=CC=C3)NC4=CC=C(C=C4)CN5CCCCC5 |
EOS-AX1777 | AMG-900 | 945595-80-2 | C28H21N7OS | 503.58 | CC1=CSC(=C1)C2=NN=C(C3=CC=CC=C32)NC4=CC=C(C=C4)OC5=C(C=CC=N5)C6=NC(=NC=C6)N |
EOS-AX1778 | MK-5108 (VX-689) | 1010085-13-8 | C22H21ClFN3O3S | 461.94 | C1CC(CCC1OC2=C(C(=CC=C2)Cl)F)(CC3=NC(=CC=C3)NC4=NC=CS4)C(=O)O |
EOS-AX1779 | SNS-314 Mesylate | 1146618-41-8 | C18H15ClN6OS2.CH4O3S | 527.04 | CS(=O)(=O)O.C1=CC(=CC(=C1)Cl)NC(=O)NC2=NC=C(S2)CCNC3=NC=NC4=C3SC=C4 |
EOS-AX1780 | PHA-680632 | 398493-79-3 | C28H35N7O2 | 501.62 | CCC1=C(C(=CC=C1)CC)NC(=O)N2CC3=C(C2)NN=C3NC(=O)C4=CC=C(C=C4)N5CCN(CC5)C |
EOS-AX1781 | KW 2449 | 1000669-72-6 | C20H20N4O | 332.4 | C1CN(CCN1)C(=O)C2=CC=C(C=C2)C=CC3=NNC4=CC=CC=C43 |
EOS-AX1782 | TAK-901 | 934541-31-8 | C28H32N4O3S | 504.64 | CCS(=O)(=O)C1=CC=CC(=C1)C2=CC(=C(C3=C2C4=CC(=CN=C4N3)C)C)C(=O)NC5CCN(CC5)C |
EOS-AX1783 | CYC116 | 693228-63-6 | C18H20N6OS | 368.46 | CC1=C(SC(=N1)N)C2=NC(=NC=C2)NC3=CC=C(C=C3)N4CCOCC4 |
EOS-AX1784 | Aurora A Inhibitor I | 1158838-45-9 | C31H31ClFN7O2 | 588.07 | CCN1CCN(CC1)C(=O)CC2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4=CC=C(C=C4)C(=O)NC5=CC=CC=C5Cl)F |
EOS-AX1785 | GSK1070916 | 942918-07-2 | C30H33N7O | 507.63 | CCN1C=C(C(=N1)C2=CC=C(C=C2)NC(=O)N(C)C)C3=C4C=C(NC4=NC=C3)C5=CC(=CC=C5)CN(C)C |
EOS-AX1786 | PF-03814735 | 942487-16-3 | C23H25F3N6O2 | 474.48 | CC(=O)NCC(=O)N1C2CCC1C3=C2C=CC(=C3)NC4=NC=C(C(=N4)NC5CCC5)C(F)(F)F |
EOS-AX1787 | ENMD-2076 L-(+)-Tartaric acid | 1291074-87-7 | C25H31N7O6 | 525.56 | CC1=CC(=NN1)NC2=NC(=NC(=C2)N3CCN(CC3)C)C=CC4=CC=CC=C4.C(C(C(=O)O)O)(C(=O)O)O |
EOS-AX1788 | ENMD-2076 | 934353-76-1 | C21H25N7 | 375.47 | CC1=CC(=NN1)NC2=NC(=NC(=C2)N3CCN(CC3)C)C=CC4=CC=CC=C4 |
EOS-AX1789 | CCT129202 | 942947-93-5 | C23H25ClN8OS | 497.02 | CN(C)C1=CC=C(C=C1)C2=NC3=NC=C(C(=C3N2)N4CCN(CC4)CC(=O)NC5=NC=CS5)Cl |
EOS-AX1790 | CCT137690 | 1095382-05-0 | C26H31BrN8O | 551.48 | CC1=CC(=NO1)CN2CCN(CC2)C3=C4C(=NC=C3Br)N=C(N4)C5=CC=C(C=C5)N6CCN(CC6)C |
EOS-AX1791 | Tofacitinib (CP-690550) Citrate | 540737-29-9 | C16H20N6O.C6H8O7 | 504.49 | CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O |
EOS-AX1792 | TG101348 (SAR302503) | 936091-26-8 | C27H36N6O3S | 524.68 | CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4 |
EOS-AX1793 | AZD1480 | 935666-88-9 | C14H14ClFN8 | 348.77 | CC1=CC(=NN1)NC2=NC(=NC=C2Cl)NC(C)C3=NC=C(C=N3)F |
EOS-AX1794 | Tofacitinib (CP-690550,Tasocitinib) | 477600-75-2 | C16H20N6O | 312.37 | CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N |
EOS-AX1795 | AG-490 | 133550-30-8 | C17H14N2O3 | 294.3 | C1=CC=C(C=C1)CNC(=O)C(=CC2=CC(=C(C=C2)O)O)C#N |
EOS-AX1796 | WP1066 | 857064-38-1 | C17H14BrN3O | 356.22 | CC(C1=CC=CC=C1)NC(=O)C(=CC2=NC(=CC=C2)Br)C#N |
EOS-AX1797 | Baricitinib (LY3009104, INCB028050) | 1187594-09-7 | C16H17N7O2S | 371.42 | CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3 |
EOS-AX1798 | CYT387 | 1056634-68-4 | C23H22N6O2 | 414.46 | C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N |
EOS-AX1799 | AZ 960 | 905586-69-8 | C18H16F2N6 | 354.36 | CC1=CC(=NN1)NC2=C(C=C(C(=N2)NC(C)C3=CC=C(C=C3)F)C#N)F |
EOS-AX1800 | TG101209 | 936091-14-4 | C26H35N7O2S | 509.67 | CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)N4CCN(CC4)C |
EOS-AX1801 | CEP-33779 | 1257704-57-6 | C24H26N6O2S | 462.57 | CN1CCN(CC1)C2=CC(=CC=C2)NC3=NN4C=CC=C(C4=N3)C5=CC=C(C=C5)S(=O)(=O)C |
EOS-AX1802 | LY2784544 | 1229236-86-5 | C23H25ClFN7O | 469.94 | CC1=CC(=NN1)NC2=NN3C(=C(N=C3C(=C2)CN4CCOCC4)C)CC5=C(C=C(C=C5)Cl)F |
EOS-AX1803 | NVP-BSK805 2HCl | 1092499-93-8 | C27H28F2N6O.2HCl | 563.47 | C1CNCCC1N2C=C(C=N2)C3=NC4=C(C=CC=C4N=C3)C5=CC(=C(C(=C5)F)CN6CCOCC6)F.Cl.Cl |
EOS-AX1804 | S-Ruxolitinib (INCB018424) | 941685-37-6 | C17H18N6 | 306.37 | C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3 |
EOS-AX1805 | WHI-P154 | 211555-04-3 | C16H14BrN3O3 | 376.2 | COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)O)Br)OC |
EOS-AX1806 | ZM 39923 HCl | 1021868-92-7 | C23H25NO.HCl | 367.91 | CC(C)N(CC1=CC=CC=C1)CCC(C2=CC3=CC=CC=C3C=C2)=O.Cl |
EOS-AX1807 | BMS-911543 | 1271022-90-2 | C23H28N8O | 432.52 | CCN1C(=CC2=C3C(=C(N=C21)NC4=NN(C(=C4)C)C)N=CN3C)C(=O)N(C5CC5)C6CC6 |
EOS-AX1808 | BMN 673 | 1207456-01-6 | C19H14F2N6O | 380.35 | FC1=CC2=N[C@@H](C(C=C3)=CC=C3F)[C@H](C4=NC=NN4C)C(NNC5=O)=C2C5=C1 |
EOS-AX1809 | Olaparib (AZD2281, Ku-0059436) | 763113-22-0 | C24H23FN4O3 | 434.46 | C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F |
EOS-AX1810 | Rucaparib (AG-014699,PF-01367338) | 459868-92-9 | C19H18FN3O.H3PO4 | 421.36 | OP(O)(O)=O.FC1=CC2=C3C(CCNC2=O)=C(C4=CC=C(CNC)C=C4)NC3=C1 |
EOS-AX1811 | Iniparib (BSI-201) | 160003-66-7 | C7H5IN2O3 | 292.03 | C1=CC(=C(C=C1C(=O)N)[N+](=O)[O-])I |
EOS-AX1812 | AG-14361 | 328543-09-5 | C19H20N4O | 320.39 | O=C1N([H])C([H])([H])C([H])([H])N2C3=C1C([H])=C([H])C([H])=C3N=C2C(C([H])=C4[H])=C([H])C([H])=C4C([H])([H])N(C([H])([H])[H])C([H])([H])[H] |
EOS-AX1813 | PJ34 hydrochloride | 344458-15-7 | C17H17N3O2.HCl | 331.8 | CN(C)CC(=O)NC1=CC2=C(C=C1)NC(=O)C3=CC=CC=C32.Cl |
EOS-AX1814 | A-966492 | 934162-61-5 | C18H17FN4O | 324.35 | C1CC(NC1)C2=CC(=C(C=C2)C3=NC4=C(C=CC=C4N3)C(=O)N)F |
EOS-AX1815 | INO-1001 | 3544-24-9 | C7H8N2O | 136.15 | C1=CC(=CC(=C1)N)C(=O)N |
EOS-AX1816 | UPF 1069 | 1048371-03-4 | C17H13NO3 | 279.29 | C1=CC=C(C=C1)C(=O)COC2=CC=CC3=C2C=CNC3=O |
EOS-AX1817 | AZD2461 | 1174043-16-3 | C22H22FN3O3 | 395.43 | COC1CCN(CC1)C(=O)C2=C(C=CC(=C2)CC3=NNC(=O)C4=CC=CC=C43)F |
EOS-AX1818 | EPZ5676 | 1380288-87-8 | C30H42N8O3 | 562.71 | CC(C)N(CC1C(C(C(O1)N2C=NC3=C2N=CN=C3N)O)O)C4CC(C4)CCC5=NC6=C(N5)C=C(C=C6)C(C)(C)C |
EOS-AX1819 | SGC 0946 | 1561178-17-3 | C28H40BrN7O4 | 618.57 | CC(C)(C)C1=CC=C(NC(NCCCN(C[C@@H]2[C@@H](O)[C@@H](O)[C@H](N3C4=NC=NC(N)=C4C(Br)=C3)O2)C(C)C)=O)C=C1 |
EOS-AX1820 | Entacapone | 130929-57-6 | C14H15N3O5 | 305.29 | CCN(CC)C(=O)C(=CC1=CC(=C(C(=C1)O)O)[N+](=O)[O-])C#N |
EOS-AX1821 | EPZ004777 | 1338466-77-5 | C28H41N7O4 | 539.67 | CC(C)N(CCCNC(=O)NC1=CC=C(C=C1)C(C)(C)C)CC2C(C(C(O2)N3C=CC4=C3N=CN=C4N)O)O |
EOS-AX1822 | EPZ005687 | 1396772-26-1 | C32H37N5O3 | 539.67 | CC1=CC(=C(C(=O)N1)CNC(=O)C2=C3C=NN(C3=CC(=C2)C4=CC=C(C=C4)CN5CCOCC5)C6CCCC6)C |
EOS-AX1823 | Decitabine(NSC127716, 5AZA-CdR) | 2353-33-5 | C8H12N4O4 | 228.21 | |
EOS-AX1824 | Azacitidine | 320-67-2 | C8H12N4O5 | 244.2 | |
EOS-AX1825 | RG108 | 48208-26-0 | C19H14N2O4 | 334.33 | |
EOS-AX1826 | Thioguanine | 154-42-7 | C5H5N5S | 167.19 | C1=NC2=C(N1)C(=S)N=C(N2)N |
EOS-AX1827 | SGI-110 | 929901-49-5 | C18H24N9O10P | 557.41 | C1C(C(OC1N2C=NC3=C2NC(=NC3=O)N)COP(=O)(O)OC4CC(OC4CO)N5C=NC(=NC5=O)N)O |
EOS-AX1828 | Lomeguatrib | 192441-08-0 | C10H8BrN5OS | 326.17 | |
EOS-AX1829 | SRT1720 HCl | 1001645-58-4 | C25H23N7OS.HCl | 506.02 | C1CN(CCN1)CC2=CSC3=NC(=CN23)C4=CC=CC=C4NC(=O)C5=NC6=CC=CC=C6N=C5.Cl |
EOS-AX1830 | EX 527 (SEN0014196) | 49843-98-3 | C13H13ClN2O | 248.71 | C1CC(C2=C(C1)C3=C(N2)C=CC(=C3)Cl)C(=O)N |
EOS-AX1831 | Resveratrol | 501-36-0 | C14H12O3 | 228.24 | C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O |
EOS-AX1832 | Sirtinol | 410536-97-9 | C26H22N2O2 | 394.47 | CC(C1=CC=CC=C1)NC(=O)C2=CC=CC=C2NC=C3C(=O)C=CC4=CC=CC=C43 |
EOS-AX1833 | PFI-1 (PF-6405761) | 1403764-72-6 | C16H17N3O4S | 347.39 | CN1CC2=C(C=CC(=C2)NS(=O)(=O)C3=CC=CC=C3OC)NC1=O |
EOS-AX1834 | Bromosporine | 1619994-69-2 | C17H20N6O4S | 404.44 | CC1=C(NS(C)(=O)=O)C=C(C2=NN3C(C(NC(OCC)=O)=C2)=NN=C3C)C=C1 |
EOS-AX1835 | FG-4592 (ASP1517) | 808118-40-3 | C19H16N2O5 | 352.34 | CC1=NC(=C(C2=C1C=C(C=C2)OC3=CC=CC=C3)O)C(=O)NCC(=O)O |
EOS-AX1836 | 2-Methoxyestradiol (2-MeOE2) | 362-07-2 | C19H26O3 | 302.41 | CC12CCC3C(C1CCC2O)CCC4=CC(=C(C=C34)OC)O |
EOS-AX1837 | IOX2(Glycine) | 931398-72-0 | C19H16N2O5 | 352.34 | C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=C(C2=O)C(=O)NCC(=O)O)O |
EOS-AX1838 | GSK J4 HCl | 1373423-53-0 | C24H27N5O2.HCl | 453.96 | CCOC(=O)CCNC1=NC(=NC(=C1)N2CCC3=CC=CC=C3CC2)C4=CC=CC=N4.Cl |
EOS-AX1839 | GSK J1 | 1373422-53-7 | C22H23N5O2 | 389.45 | C1CN(CCC2=CC=CC=C21)C3=CC(=NC(=N3)C4=CC=CC=N4)NCCC(=O)O |
EOS-AX1840 | SGI-1776 free base | 1025065-69-3 | C20H22F3N5O | 405.42 | CN1CCC(CC1)CNC2=NN3C(=NC=C3C4=CC(=CC=C4)OC(F)(F)F)C=C2 |
EOS-AX1841 | SMI-4a | 438190-29-5 | C11H6F3NO2S | 273.23 | C1=CC(=CC(=C1)C(F)(F)F)C=C2C(=O)NC(=O)S2 |
EOS-AX1842 | Obatoclax mesylate (GX15-070) | 803712-79-0 | C20H19N3O.CH4O3S | 413.5 | CC1=CC(=C(N1)C=C2C(=CC(=C3C=C4C=CC=CC4=N3)N2)OC)C.CS(=O)(=O)O |
EOS-AX1843 | AT101 | 866541-93-7 | C30H30O8.C2H4O2 | 578.61 | |
EOS-AX1844 | BM-1074 | 1391108-10-3 | C50H57ClN8O7S3 | 1013.68 | CC(N1C(C)=C(/C(O)=N/S(C)(=O)=O)C(C2=CC(N3CCN(C4=CC=C(NS(C5=CC(N(=O)=O)=C(N[C@](CSC6=CC=CC=C6)([H])CCN(C)C)C=C5)(=O)=O)C=C4)CC3)=CC=C2)=C1C7=CC=C(Cl)C=C7)C |
EOS-AX1845 | Sabutoclax | 1228108-65-3 | C42H40N2O8 | 700.78 | CC1=C(C(=C2C=C(C(=C(C2=C1)C(=O)NCC(C)C3=CC=CC=C3)O)O)O)C4=C(C=C5C(=C4O)C=C(C(=C5C(=O)NCC(C)C6=CC=CC=C6)O)O)C |
EOS-AX1846 | Apogossypolone (ApoG2) | 886578-07-0 | C28H26O8 | 490.501 | CC1=C(C2=C(C(=O)C(=O)C=C2C(=C1C3=C(C4=CC(=O)C(=O)C(=C4C(=C3C)O)C(C)C)O)O)C(C)C)O |
EOS-AX1847 | RITA (NSC 652287) | 213261-59-7 | C14H12O3S2 | 292.4 | C1=C(SC(=C1)C2=CC=C(O2)C3=CC=C(S3)CO)CO |
EOS-AX1848 | Tenovin-1 | 380315-80-0 | C20H23N3O2S | 369.5 | CC(=O)NC1=CC=C(C=C1)NC(=S)NC(=O)C2=CC=C(C=C2)C(C)(C)C |
EOS-AX1849 | JNJ-26854165 (Serdemetan) | 881202-45-5 | C21H20N4 | 328.41 | C1=CC=C2C(=C1)C(=CN2)CCNC3=CC=C(C=C3)NC4=CC=NC=C4 |
EOS-AX1850 | Pifithrin-α (PFTα) | 63208-82-2 | C16H18N2OS.HBr | 367.3 | CC1=CC=C(C=C1)C(=O)CN2C3=C(CCCC3)SC2=N.Br |
EOS-AX1851 | NSC 319726 | 71555-25-4 | C11H14N4S | 234.32 | CC(=NNC(=S)N1CCC1)C2=CC=CC=N2 |
EOS-AX1852 | NSC 207895 (XI-006) | 58131-57-0 | C11H13N5O4 | 279.25 | CN1CCN(CC1)C2=CC=C(C3=NO[N+](=C23)[O-])[N+](=O)[O-] |
EOS-AX1853 | Bay 11-7821(BAY 11-7082) | 19542-67-7 | C10H9NO2S | 207.25 | CC1=CC=C(C=C1)S(=O)(=O)C=CC#N |
EOS-AX1854 | Lenalidomide (CC-5013) | 191732-72-6 | C13H13N3O3 | 259.3 | C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N |
EOS-AX1855 | Pomalidomide (CC-4047) | 19171-19-8 | C13H11N3O4 | 273.2 | C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N |
EOS-AX1856 | Necrostatin-1 | 4311-88-0 | C13H13N3OS | 259.33 | CN1C(=O)C(NC1=S)CC2=CNC3=CC=CC=C32 |
EOS-AX1857 | Thalidomide | 50-35-1 | C13H10N2O4 | 258.23 | C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O |
EOS-AX1858 | QNZ (EVP4593) | 545380-34-5 | C22H20N4O | 356.42 | C1=CC=C(C=C1)OC2=CC=C(C=C2)CCNC3=NC=NC4=C3C=C(C=C4)N |
EOS-AX1859 | Birinapant (TL32711) | 1260251-31-7 | C42H56F2N8O6 | 806.94 | CCC(C(=O)N1CC(CC1CC2=C(NC3=C2C=CC(=C3)F)C4=C(C5=C(N4)C=C(C=C5)F)CC6CC(CN6C(=O)C(CC)NC(=O)C(C)NC)O)O)NC(=O)C(C)NC |
EOS-AX1860 | LCL-161 | 1005342-46-0 | C26H33FN4O3S | 500.2 | |
EOS-AX1861 | YM155 | 781661-94-7 | C20H19BrN4O3 | 443.3 | CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Br-] |
EOS-AX1862 | AT406 (SM-406) | 1071992-99-8 | C32H43N5O4 | 561.71 | |
EOS-AX1863 | GDC-0152 | 873652-48-3 | C25H34N6O3S | 498.64 | CC(C(=O)NC(C1CCCCC1)C(=O)N2CCCC2C(=O)NC3=C(N=NS3)C4=CC=CC=C4)NC |
EOS-AX1864 | PF-3758309 | 898044-15-0 | C25H30N8OS | 490.2 | |
EOS-AX1865 | Pluripotin (SC-1) | 839707-37-8 | C27H25F3N8O2 | 550.5 | |
EOS-AX1866 | Tipifarnib (Zarnestra) | 192185-72-1 | C27H22Cl2N4O | 489.4 | CN1C=NC=C1C(C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC(=CC=C5)Cl)C)N |
EOS-AX1867 | Nutlin-3 | 890090-75-2 | C30H30Cl2N4O4 | 581.5 | CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl |
EOS-AX1868 | NSC 66811 | 6964-62-1 | C23H20N2O | 340.42 | CC1=NC2=C(C=C1)C=CC(=C2O)C(C3=CC=CC=C3)NC4=CC=CC=C4 |
EOS-AX1869 | SL-01 | 26049-94-5 | C18H18ClNO3 | 331.79 | |
EOS-AX1870 | Cyclophosphamide monohydrate | 6055-19-2 | C7H15Cl2N2O2P.H2O | 279.1 | C1CNP(=O)(OC1)N(CCCl)CCCl.O |
EOS-AX1871 | Methylprednisolone | 83-43-2 | C22H30O5 | 374.48 | CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O |
EOS-AX1872 | TW-37 | 877877-35-5 | C33H35NO6S | 573.7 | CC(C)C1=CC=CC=C1CC2=C(C(=C(C(=C2)C(=O)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=CC=C4C(C)(C)C)O)O)O |
EOS-AX1873 | Amuvatinib (MP-470, HPK 56) | 850879-09-3 | C23H21N5O3S | 447.51 | C1CN(CCN1C2=NC=NC3=C2OC4=CC=CC=C43)C(=S)NCC5=CC6=C(C=C5)OCO6 |
EOS-AX1874 | Abiraterone | 154229-19-3 | C24H31NO | 349.52 | CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O |
EOS-AX1875 | GW9662 | 22978-25-2 | C13H9ClN2O3 | 276.68 | C1=CC=C(C=C1)NC(=O)C2=C(C=CC(=C2)[N+](=O)[O-])Cl |
EOS-AX1876 | T0070907 | 313516-66-4 | C12H8ClN3O3 | 277.66 | C1=CC(=C(C=C1[N+](=O)[O-])C(=O)NC2=CC=NC=C2)Cl |
EOS-AX1877 | Rosiglitazone maleate | 155141-29-0 | C18H19N3O3S.C4H4O4 | 473.5 | CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3.C(=CC(=O)O)C(=O)O |
EOS-AX1878 | GSK3787 | 188591-46-0 | C15H12ClF3N2O3S | 392.78 | C1=CC(=CC=C1C(=O)NCCS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)Cl |
EOS-AX1879 | Rosiglitazone | 122320-73-4 | C18H19N3O3S | 357.43 | CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3 |
EOS-AX1880 | WY-14643 (Pirinixic Acid) | 50892-23-4 | C14H14ClN3O2S | 323.8 | CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C |
EOS-AX1881 | Ciprofibrate | 52214-84-3 | C13H14Cl2O3 | 289.15 | CC(C(O)=O)(OC1=CC=C(C2CC2(Cl)Cl)C=C1)C |
EOS-AX1882 | GW0742 | 317318-84-6 | C21H17F4NO3S2 | 471.49 | CC1=C(C=CC(=C1)SCC2=C(N=C(S2)C3=CC(=C(C=C3)C(F)(F)F)F)C)OCC(=O)O |
EOS-AX1883 | Alizarin | 72-48-0 | C14H8O4 | 240.21 | O=C(C1=C2C(O)=C(O)C=C1)C3=CC=CC=C3C2=O |
EOS-AX1884 | GW501516 | 317318-70-0 | C21H18F3NO3S2 | 453.5 | CC1=C(C=CC(=C1)SCC2=C(N=C(S2)C3=CC=C(C=C3)C(F)(F)F)C)OCC(=O)O |
EOS-AX1885 | Rosiglitazone HCl | 302543-62-0 | C18H20ClN3O3S | 393.89 | CN(C1=CC=CC=N1)CCOC2=CC=C(CC3C(NC(S3)=O)=O)C=C2.Cl |
EOS-AX1886 | PF-4981517 | 1390637-82-7 | C26H32N8 | 456.59 | CC1=CC=C(C=C1)C2=C(C=NN2C)C3=NN(C4=C3C(=NC=N4)N5CCC(C5)N6CCCCC6)C |
EOS-AX1887 | Cobicistat (GS-9350) | 1004316-88-4 | C40H53N7O5S2 | 776.02 | CC(C1=NC(CN(C(NC(C(NC(CC2=CC=CC=C2)CCC(NC(OCC3=CN=CS3)=O)CC4=CC=CC=C4)=O)CCN5CCOCC5)=O)C)=CS1)C |
EOS-AX1888 | Ketoconazole | 65277-42-1 | C26H28Cl2N4O4 | 531.43 | CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl |
EOS-AX1889 | Apremilast (CC-10004) | 608141-41-9 | C22H24N2O7S | 460.5 | CCOC1=C(C=CC(=C1)C(CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC |
EOS-AX1890 | Avasimibe | 166518-60-1 | C29H43NO4S | 501.72 | CC(C)C1=C(C(=CC=C1)C(C)C)OS(=O)(=O)NC(=O)CC2=C(C=C(C=C2C(C)C)C(C)C)C(C)C |
EOS-AX1891 | Roflumilast | 162401-32-3 | C17H14Cl2F2N2O3 | 403.21 | C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F |
EOS-AX1892 | Voriconazole | 137234-62-9 | C16H14F3N5O | 349.31 | CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O |
EOS-AX1893 | Sildenafil Citrate | 171599-83-0 | C22H30N6O4S.C6H8O7 | 666.7 | CCCC1=NN(C2=C1NC(=NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O |
EOS-AX1894 | Clarithromycin | 81103-11-9 | C38H69NO13 | 747.95 | CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)O)(C)O |
EOS-AX1895 | Vardenafil HCl Trihydrate | 224785-90-4 | C23H32N6O4S.HCl.3H2O | 579.11 | CCCC1=NC(=C2N1NC(=NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC)C |
EOS-AX1896 | Pioglitazone HCl | 112529-15-4 | C19H20N2O3S.HCl | 392.9 | CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3.Cl |
EOS-AX1897 | PF-2545920 | 1292799-56-4 | C25H20N4O | 392.45 | CN1C=C(C(=N1)C2=CC=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)C5=CC=NC=C5 |
EOS-AX1898 | TAK-700 (Orteronel) | 426219-18-3 | C18H17N3O2 | 307.35 | CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)C3(CCN4C3=CN=C4)O |
EOS-AX1899 | Tadalafil | 171596-29-5 | C22H19N3O4 | 389.4 | O=C1N(C)CC(N([C@@H]2C(C=C3)=CC4=C3OCO4)[C@]1([H])CC5=C2NC6=CC=CC=C56)=O |
EOS-AX1900 | Rolipram | 61413-54-5 | C16H21NO3 | 275.34 | COC1=C(C=C(C=C1)C2CC(=O)NC2)OC3CCCC3 |
EOS-AX1901 | Cilomilast | 153259-65-5 | C20H25NO4 | 343.42 | COC1=C(C=C(C=C1)C2(CCC(CC2)C(=O)O)C#N)OC3CCCC3 |
EOS-AX1902 | Isotretinoin | 4759-48-2 | C20H28O2 | 300.44 | CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C |
EOS-AX1903 | GSK256066 | 801312-28-7 | C27H26N4O5S | 518.58 | CC1=C2C(=CC(=C1)S(=O)(=O)C3=CC=CC(=C3)C(=O)N(C)C)C(=C(C=N2)C(=O)N)NC4=CC(=CC=C4)OC |
EOS-AX1904 | Nepicastat (SYN-117) HCl | 170151-24-3 | C14H15F2N3S.HCl | 331.81 | C1CC2=C(C=C(C=C2CC1N3C(=CNC3=S)CN)F)F.Cl |
EOS-AX1905 | CPI-613 | 95809-78-2 | C22H28O2S2 | 388.59 | C1=CC=C(C=C1)CSCCC(CCCCC(=O)O)SCC2=CC=CC=C2 |
EOS-AX1906 | Avanafil | 330784-47-9 | C23H26ClN7O3 | 483.95 | O=C(C1=CN=C(N2[C@H](CO)CCC2)N=C1NCC3=CC=C(OC)C(Cl)=C3)NCC4=NC=CC=N4 |
EOS-AX1907 | Mildronate | 76144-81-5 | C6H14N2O2 | 147.19 | C[N+](C)(C)NCCC(=O)[O-] |
EOS-AX1908 | Mycophenolate Mofetil | 128794-94-5 | C23H31NO7 | 433.49 | CC1=C(C(=C(C2=C1COC2=O)O)CC=C(C)CCC(=O)OCCN3CCOCC3)OC |
EOS-AX1909 | Cilostazol | 73963-72-1 | C20H27N5O2 | 369.46 | C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4 |
EOS-AX1910 | Rivaroxaban | 366789-02-8 | C19H18ClN3O5S | 435.88 | C1COCC(=O)N1C2=CC=C(C=C2)N3CC(OC3=O)CNC(=O)C4=CC=C(S4)Cl |
EOS-AX1911 | AGI-5198 | 1355326-35-0 | C27H31FN4O2 | 462.56 | CC1=CC=CC=C1C(C(=O)NC2CCCCC2)N(C3=CC(=CC=C3)F)C(=O)CN4C=CN=C4C |
EOS-AX1912 | Pimobendan | 74150-27-9 | C19H18N4O2 | 334.37 | CC1CC(=O)NN=C1C2=CC3=C(C=C2)N=C(N3)C4=CC=C(C=C4)OC |
EOS-AX1913 | Apixaban | 503612-47-3 | C25H25N5O4 | 459.5 | COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N |
EOS-AX1914 | Gimeracil | 103766-25-2 | C5H4ClNO2 | 145.54 | C1=C(C(=CNC1=O)Cl)O |
EOS-AX1915 | Dyphylline | 479-18-5 | C10H14N4O4 | 254.24 | CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O |
EOS-AX1916 | Ozagrel | 82571-53-7 | C13H12N2O2 | 228.25 | C1=CC(=CC=C1CN2C=CN=C2)C=CC(=O)O |
EOS-AX1917 | MK-8245 | 1030612-90-8 | C17H16BrFN6O4 | 467.25 | C1CN(CCC1OC2=C(C=CC(=C2)F)Br)C3=NOC(=C3)C4=NN(N=N4)CC(=O)O |
EOS-AX1918 | Aminophylline | 317-34-0 | C16H24N10O4 | 420.43 | CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N |
EOS-AX1919 | Methotrexate | 59-05-2 | C20H22N8O5 | 454.44 | CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O |
EOS-AX1920 | Trilostane | 13647-35-3 | C20H27NO3 | 329.43 | N#CC1=C([C@@]2([H])O[C@@]2(C([H])([H])C3([H])[H])[C@@](C1([H])[H])(C([H])([H])[H])[C@]4([H])[C@]3([H])[C@@](C([H])([H])C([H])([H])[C@]5([H])O[H])([H])[C@]5(C([H])([H])[H])C([H])([H])C4([H])[H])O[H] |
EOS-AX1921 | S- (+)-Rolipram | 85416-73-5 | C16H21NO3 | 275.34 | COC1=C(C=C(C=C1)C2CC(=O)NC2)OC3CCCC3 |
EOS-AX1922 | Pralatrexate | 146464-95-1 | C23H23N7O5 | 477.47 | C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O |
EOS-AX1923 | PluriSIn #1 (NSC 14613) | 91396-88-2 | C12H11N3O | 213.24 | C1=CC=C(C=C1)NNC(=O)C2=CC=NC=C2 |
EOS-AX1924 | Anagrelide HCl | 58579-51-4 | C10H8Cl3N3O | 292.55 | C1C2=C(C=CC(=C2Cl)Cl)NC3=NC(=O)CN31.Cl |
EOS-AX1925 | Pyrimethamine | 58-14-0 | C12H13ClN4 | 248.71 | CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl |
EOS-AX1926 | UK 383367 | 348622-88-8 | C15H24N4O4 | 324.38 | C1CCC(CC1)CCCC(CC(=O)NO)C2=NC(=NO2)C(=O)N |
EOS-AX1927 | Tosedostat (CHR2797) | 238750-77-1 | C21H30N2O6 | 406.47 | CC(C)CC(C(C(=O)NO)O)C(=O)NC(C1=CC=CC=C1)C(=O)OC2CCCC2 |
EOS-AX1928 | Varespladib (LY315920) | 172732-68-2 | C21H20N2O5 | 380.39 | CCC1=C(C2=C(N1CC3=CC=CC=C3)C=CC=C2OCC(=O)O)C(=O)C(=O)N |
EOS-AX1929 | Dorzolamide HCl | 130693-82-2 | C10H16N2O4S3.HCl | 360.9 | CCNC1CC(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C.Cl |
EOS-AX1930 | U-104 | 178606-66-1 | C13H12FN3O3S | 309.32 | C1=CC(=CC=C1NC(=O)NC2=CC=C(C=C2)S(=O)(=O)N)F |
EOS-AX1931 | Brinzolamide | 138890-62-7 | C12H21N3O5S3 | 383.51 | O=S(C(S1)=CC2=C1S(N(CCCOC)C[C@@H]2NCC)(=O)=O)(N)=O |
EOS-AX1932 | Topiramate | 97240-79-4 | C12H21NO8S | 339.36 | CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C |
EOS-AX1933 | JNJ-1661010 | 681136-29-8 | C19H19N5OS | 365.45 | C1CN(CCN1C2=NC(=NS2)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4 |
EOS-AX1934 | Tioxolone | 4991-65-5 | C7H4O3S | 168.17 | OC1=CC(OC(S2)=O)=C2C=C1 |
EOS-AX1935 | Fluvastatin Sodium | 93957-55-2 | C24H25FNNaO4 | 433.45 | CC(C)N1C2=CC=CC=C2C(=C1C=CC(CC(CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+] |
EOS-AX1936 | Methazolamide | 554-57-4 | C5H8N4O3S2 | 236.27 | CC(=O)N=C1N(N=C(S1)S(=O)(=O)N)C |
EOS-AX1937 | Lovastatin | 75330-75-5 | C24H36O5 | 404.54 | CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C |
EOS-AX1938 | Rasagiline Mesylate | 161735-79-1 | C12H13N.CH4O3S | 267.34 | CS(=O)(=O)O.C#CCNC1CCC2=CC=CC=C12 |
EOS-AX1939 | Atorvastatin Calcium | 134523-03-8 | 2(C33H34FN2O5).Ca | 1155.34 | CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)[O-])O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4.CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)[O-])O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4.[Ca+2] |
EOS-AX1940 | Safinamide Mesylate | 202825-46-5 | C17H19FN2O2.CH4O3S | 398.45 | CC(C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)F.CS(=O)(=O)O |
EOS-AX1941 | Pravastatin sodium | 81131-70-6 | C23H35O7.Na | 446.51 | CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)[O-])O)O)O.[Na+] |
EOS-AX1942 | Moclobemide (Ro 111163) | 71320-77-9 | C13H17ClN2O2 | 268.74 | C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl |
EOS-AX1943 | Ferrostatin-1 (Fer-1) | 347174-05-4 | C15H22N2O2 | 262.35 | NC1=C(NC2CCCCC2)C=CC(C(OCC)=O)=C1 |
EOS-AX1944 | URB597 | 546141-08-6 | C20H22N2O3 | 338.4 | C1CCC(CC1)NC(=O)OC2=CC=CC(=C2)C3=CC(=CC=C3)C(=O)N |
EOS-AX1945 | NLG919 | 1402836-58-1 | C18H22N2O | 282.38 | C1CCC(CC1)C(CC2C3=CC=CC=C3C4=CN=CN24)O |
EOS-AX1946 | PF-3845 | 1196109-52-0 | C24H23F3N4O2 | 456.46 | C1CN(CCC1CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=CN=CC=C4 |
EOS-AX1947 | Anacetrapib (MK-0859) | 875446-37-0 | C30H25F10NO3 | 637.51 | CC1C(OC(=O)N1CC2=C(C=CC(=C2)C(F)(F)F)C3=CC(=C(C=C3OC)F)C(C)C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F |
EOS-AX1948 | Dalcetrapib (JTT-705, RO4607381) | 211513-37-0 | C23H35NO2S | 389.59 | CCC(CC)CC1(CCCCC1)C(=O)NC2=CC=CC=C2SC(=O)C(C)C |
EOS-AX1949 | Evacetrapib (LY2484595) | 1186486-62-3 | C31H36F6N6O2 | 638.65 | CC1=CC(=C2C(=C1)C(CCCN2CC3CCC(CC3)C(=O)O)N(CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=NN(N=N5)C)C |
EOS-AX1950 | Torcetrapib | 262352-17-0 | C26H25F9N2O4 | 600.47 | CCC1CC(C2=C(N1C(=O)OCC)C=CC(=C2)C(F)(F)F)N(CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C(=O)OC |
EOS-AX1951 | Lonafarnib | 193275-84-2 | C27H31Br2ClN4O2 | 638.82 | C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(C=C(C=C4CCC5=CC(=CN=C35)Br)Cl)Br)C(=O)N |
EOS-AX1952 | FK866 (APO866) | 658084-64-1 | C24H29N3O2 | 391.51 | C1CN(CCC1CCCCNC(=O)C=CC2=CN=CC=C2)C(=O)C3=CC=CC=C3 |
EOS-AX1953 | A922500 | 959122-11-3 | C26H24N2O4 | 428.48 | C1CC(C(C1)C(=O)O)C(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)NC(=O)NC4=CC=CC=C4 |
EOS-AX1954 | Tolcapone | 134308-13-7 | C14H11NO5 | 273.24 | CC1=CC=C(C=C1)C(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-] |
EOS-AX1955 | PF-04620110 | 1109276-89-2 | C21H24N4O4 | 396.44 | C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)N3CCOC4=NC=NC(=C4C3=O)N |
EOS-AX1956 | Ganetespib (STA-9090) | 888216-25-9 | C20H20N4O3 | 364.4 | CC(C)C1=CC(=C2NNC(=O)N2C3=CC4=C(C=C3)N(C=C4)C)C(=O)C=C1O |
EOS-AX1957 | Elesclomol (STA-4783) | 488832-69-5 | C19H20N4O2S2 | 400.5 | CN(C(=S)C1=CC=CC=C1)NC(=O)CC(=O)NN(C)C(=S)C2=CC=CC=C2 |
EOS-AX1958 | VER 155008 | 1134156-31-2 | C25H23Cl2N7O4 | 556.4 | C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N |
EOS-AX1959 | XL-888 | 1149705-71-4 | C29H37N5O3 | 503.64 | CCC(C)NC1=CC(=C(C=C1C(=O)N)C)C(=O)NC2CC3CCC(C2)N3C4=NC=C(C=C4)C(=O)C5CC5 |
EOS-AX1960 | Galeterone | 851983-85-2 | C26H32N2O | 388.55 | |
EOS-AX1961 | Pemetrexed | 150399-23-8 | C20H19N5Na2O6 | 471.37 | C1=CC(=CC=C1CCC2=CNC3=C2C(=O)N=C(N3)N)C(=O)NC(CCC(=O)[O-])C(=O)[O-].[Na+].[Na+] |
EOS-AX1962 | WIN 55,212-2 mesylate | 131543-23-2 | C27H26N2O3.CH3SO3H | 522.61 |
EOS Med Chem, Medicinal Chemical is Big is China TOP 100 CRO comapny, mainly in Med-chemicals, Custom synthesis. We have GMP, ISO plant plant serving you.